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Tomorrow may never come 
For you or me 
Life is not promised 
Tomorrow may never show up 
For you and me 
This life is not promised 
 
I ain't no perfect man 
I'm trying to do, the best that I can, 
With what it is I have 
 
Put my heart and soul into this… 
I hope you feel me 
From where I am, to wherever you are 
I mean that sincerely 
Tomorrow may never come 
For you and me 
Life is not promised 
Tomorrow may never appear 
You better hold this very moment very close to you (right now) 
Very close to you (right now) 
So close to you, So- close to you (your moment in history is right now!) 
Don't be afraid, to let it shine 
 
My Umi said shine your light on the world 
Shine your light for the world to see 
My Abi said shine your light on the world 
Shine your light for the world to see 
 
 
- Umi Says by Dante Smith (a.k.a Mos Def) 
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For Mummy and Daddy. 
 I hope I let my light shine on the world.
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CHAPTER I 
 
 
INTRODUCTION 
 
 
Prostaglandin H Synthases, their Substrates and Products 
 
 
 
Historical Overview 
 
Prostaglandin H synthases (PGHS-1 and PGHS-2) also known as 
cyclooxygenases (COX-1 and COX-2) are enzymes that oxygenate fatty acid substrates 
(FAH) such as arachidonic acid (AA), leading to the generation of prostaglandins. 
Prostaglandins mediate a wide array of physiological effects, including pain, 
inflammation, fever, vascular homeostasis, and parturition. PGHS is the target of non-
steroidal anti-inflammatory drugs (NSAIDs), which prevent AA oxygenation and thus 
prostaglandin generation. The role of PGHS in mediating fever, pain and inflammation 
has unwittingly made PGHS perhaps the oldest documented drug target known to man. It 
was documented in Ebers’s papyrus in 1500 BC, that the Egyptians used NSAID 
containing willow bark extract to treat fever (1).  The importance of abating fever is 
evident in the convergent discovery by ancient denizens of separate continents; Romans, 
Native Americans, Chinese, and South African Hottentots had all established that fever 
could be reduced by NSAID-containing willow or myrtle leaf extracts (2-4). The first 
scientific record of NSAID use was by the Reverend Edward Stone, who reported to the 
Royal Society of London in 1763 that powdered willow bark improved the condition of 
fifty of his patients who were suffering from maladies manifesting fever and shivering- a 
condition archaically known as agues (4). Sixty-three years later, the French pharmacist 
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Henri Leroux isolated the active ingredient in willow bark and myrtle leaves, and named 
it salicin based on the genus of the willow plant (Salix). Leroux further demonstrated that 
it was salicin that effected willow bark’s antipyrexia (5). Salicin is a glycoside that is 
hydrolyzed to salicylic alcohol, which can be oxidized to form salicylic acid (1) (Figure 
1). Thomas MacLagan, a Scottish physician, conducted the first formal clinical trial on 
salicin in 1874. MacLagan, having experienced no untoward effects after consuming two 
grams of the compound, administered it to his patient with rheumatic fever and 
successfully reduced the patient’s fever, inflammation, and pain (6).  That same year, 
Lautemann and Kolbe developed a chemical process by which they could generate 
salicylic acid at a fraction of the cost of extracting it from willow (3). It could even be 
argued that the rise of NSAIDs led to the birth of the pharmaceutical industry; the first 
drug factory was built to mass-produce salicylic acid (7).  Although salicylic acid soon 
became the drug of choice for treating fever, pain, and inflammation, its bitterness and 
gastric side effects led to poor tolerance in some. In 1897, Felix Hoffman- a chemist at 
the Friedreich Bayer and Company- generated a more palatable form of salicylic acid by 
acetylating the alcohol on the phenol ring to form acetylsalicylic acid or aspirin (Figure 
1) (1).  The connection between the effects of NSAID use and the COX enzymes would 
not be made for another 70 years. 
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Figure 1. Salicin and its derivatives 
 
Prostaglandins were first discovered in 1930 by two gynecologists Raphael 
Kurzok and Charles Lieb, as an unidentified substance in semen, that when applied to 
uterine muscle caused it to contract (8). Over the next few years, Von Euler and Goldbatt 
independently demonstrated that plasma from semen and vesicular glands possessed an 
array of potent biological activities (9-13). Von Euler, convinced that the prostate was the 
source of these substances, christened them prostaglandins. Bergström and Samuelsson 
elucidated the structures of these new lipid derived molecules, and correctly proposed the 
mechanisms of their generation. Since the structures they had described contained 
functionalized cyclopentane rings and the oxygen atoms originated from molecular 
oxygen, they aptly named the enzyme that catalyzed the reaction cyclooxygenase (COX) 
(14). A few years later, the connection between NSAIDs and cyclooxygenase was made 
by Willis and Smith, who demonstrated that treating platelets with aspirin prevented 
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clotting along with inhibition of prostaglandin formation (15), and the late Sir John Vane, 
who demonstrated that NSAIDs could diminish the production of prostaglandins in 
guinea pig lung homogenates (16). Drawing on the well documented action of NSAIDs 
and these new discoveries, Sir John Vane proposed that inhibition of prostaglandin 
generation was how NSAIDs mediated analgesia and anti-pyrexia (16). Bergström, 
Samuelsson, and Vane shared the 1982 Nobel Prize in medicine for their seminal work 
on prostaglandins and the action of NSAIDs. 
 
The last few decades have seen an explosion in the amount of PGHS-related 
research. This is especially evident in the early 1990s, when PGHS-2 was discovered as a 
separate isozyme (17,18). It has become clear that this new protagonist had been 
surreptitiously engaged in soliloquy; playing an unappreciated role as a mediator of acute 
inflammation, pain, and cancer progression. Despite our wider understanding of PGHSs 
and their products, it is now more evident that the roles of prostaglandins in homeostasis 
is under-appreciated and poorly understood. The lack of understanding is reflected in our 
inability to explain why taking NSAIDs predisposes patients to increased risk of 
cardiovascular events (19), despite the fact that the roles of prostaglandins in vascular 
homeostasis have been well outlined. This indicates that the PGHS field remains a rich 
loam, awaiting the prepared to sew seeds of discovery. 
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Prostaglandin H Synthases 
 
 
Structure and biochemistry 
 
PGHSs are ~70 kDa heme-bearing membrane proteins, that are usually  found as ~140 
kDa homodimers (20-22). However, a report of functional PGHS-1 and PGHS-2 
heterodimers, in vivo, has been demonstrated in mice (23). PGHSs bear three domains. 
Starting at the N- terminus is an epidermal growth factor (EGF)-like domain with an 
unknown function, a membrane-binding domain that is used to insert the functional 
homodimer monotopically into the lipid bilayer, and a catalytic domain housing the 
enzyme’s spatially distinct peroxidase (POX) and cyclooxygenase (COX) functionalities 
(Figure 2) (24,25). PGHSs are evolutionarily related to myeloperoxidase (26). However, 
unlike myeloperoxidase, PGHSs bear an L-shaped hydrophobic fatty acyl (FAH) binding 
site that forms the COX active site (27) (Figure 2).  
 
Biochemistry of PGHS 
PGHSs carry out the stereo-controlled, bis-dioxygenation of polyunsaturated FAHs. Its 
primary substrate in vivo is arachidonic acid (AA), which is released from phospholipid 
stores by the action of various phospholipases on glycerophospholipids. Oxygenation of 
AA leads to the formation of an unstable 20 carbon hydroperoxy-endoperoxide known as 
prostaglandin G2 (PGG2), which diffuses out of the COX active site to the peroxidase 
active site where it is reduced to an endoperoxide alcohol, prostaglandin H2 (PGH2) (27) 
(Figure 4). Formation of PGG2 in the L-shaped hydrophobic core forming the 
cyclooxygenase active site (Figure 3), affords stereochemical and regiochemical control 
	   6	  
to the addition of the two molecules of oxygen to the FAH backbone, transforming an 
achiral substrate into one with five chiral centers (Figure 4). 
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The mechanistic linkage of the POX and COX active site was proposed as the 
branched chain mechanism by Dietz et al. (1988) (28). This mechanism, which gives 
PGHS elegant control over the process of FAH oxygenation, has been validated by the 
majority of experimental observations and is represented in its simplest form, for 
substrate AA, in Figure 5. The POX active site can function independently of the COX 
active site (29); however, PGHS’s COX activity is latent until the peroxidase active site 
heme [(PPIX)Fe3+] undergoes a two-electron oxidation, leading to the formation of an 
ferryloxoprotoporyphin cation radical [(PPIX)+Fe4+ O] (Figure 5, Step A). Similar to 
other peroxidases, two subsequent one-electron reductions of the ferryloxoprotoporyphin 
cation radical [(PPIX)+Fe4+ O] return the heme to its resting state, [(PPIX)Fe3+] (Figure 
5). Reducing co-substrates, such as phenol, epinephrine, and ascorbate, are oxidized in 
this process, and it is this necessity for a reducing co-substrate that links the POX and 
COX active sites (30). The catalytic residue in the COX active site, Tyr-385, can serve as 
the reductant (Eo’= 0.9 V) for the first one-electron reduction of the 
ferryloxoprotoporyphin cation radical [(PPIX) +Fe4+ O] (Eo = 1.0 V), a 
thermodynamically favorable reaction, leading to the formation of a tyrosyl radical at 
Tyr-385 (Figure 5, Step B)(31). This step is the critical connection between the POX and 
the COX active sites of PGHS. The Tyr-385 radical is critically positioned in the COX 
active site, enabling it to abstract a hydrogen atom from the 13-pro-(S) position of the 
backbone of AA (Eo 0.6 V) (Figure 5, Step C), another thermodynamically favorable 
event (32,33). The formation of a radical at the 13-position followed by a series of radical 
rearrangements along the AA backbone, allows the addition of two molecules of oxygen, 
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leading to the formation of the 15-hydroperoxyl radical of PGG2, which is then reduced 
by Tyr-385, regenerating the Tyr-385 radical (Figure 5, Step D).  
Note that, once formed, the Tyr-385 radical can carry out COX functionality, 
independently of the POX active site (34). However, a requirement for hydroperoxides 
for continuous COX activity has been observed (35-37).  It appears that the Tyr-385 
radical can be reduced to its latent state, a reaction competing with the abstraction of the 
13-pro-(S) hydrogen from the AA backbone (Figure 5, Step E). This indicates that the 
continuous presence of hydroperoxides in necessary to reoxidize the heme as needed to 
reactivate the Tyr385 catalytic residue.  
Studies examining the paradoxical existence of a peroxide-depleting functionality 
(POX) and a peroxide-dependent functionality (COX) in PGHS led to the demonstration 
that the POX activity of PGHS is easily suppressed in the presence of competing 
peroxide reducing glutathione peroxidase (GPx), while the COX activity of PGHS is 
refractory to this suppression (35,38,39). This was the first indication that there was a 
distinction between the concentration of peroxide required for half-maximal activity (Km) 
of the POX activity of PGHS and the concentration of peroxide required to activate the 
COX functionality of PGHS. This latter concentration, is consequently much lower than 
the Km for the POX active site and has been coined Kp (39). The Kp is a relative value that 
is determined by factoring in the Km of the peroxide in question for the POX active site of 
PGHS, and the slope of the decay of oxygenation in the face of increasing GPx 
concentrations. These values have been measured for PGHS-1 with AA as the COX 
substrate and PGG2 as the POX substrate. Whereas the Km for PGG2 at the POX active 
site of PGHS-1 is about 2 µM, the Kp for AA oxygenation is 0.2 µM (39). Part of the 
	   11	  
work described herein describes how this phenomenon can come into play when 
examining the metabolism of non-AA substrates. 
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Figure 5. The Branched Chain Mechanism and POX and COX mechanism of PGHS 
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Interestingly, PGHS also undergoes a first-order irreversible inactivation that is 
turnover-dependent (40). This phenomenon is poorly understood and is thought to 
represent a reaction of the protein with a catalytic intermediate, leading to modification of 
the enzyme (41). The nature of the modification is yet to be identified; however the 
culprit in the inactivation of the peroxidase active site has been identified as the 
ferryloxoprotoporyphin cation radical and not the Tyr-385 radical (42). Regardless, it is 
uncertain whether inactivation is a factor in vivo, since reactions with PGHS in vitro are 
carried out with excess substrate and low concentrations of PGHS. Furthermore, the 
cellular milieu of PGHS differs markedly from the in vitro conditions under which this 
phenomenon is observed. In fact, the presence of reductants has been shown to protect 
PGHS from oxidative inactivation (30).  
There are two isoforms of PGHS, PGHS-1 and PGHS-2. The discovery of the 
second isoform in the 1990s was exciting and complicated the prostanoid field even 
further. PGHS-1 and PGHS-2 from the same species share 60-65% sequence identity, and 
similar isoforms from different species are 85-90% identical. As would be expected from 
such high sequence homology, the X-ray crystal structures of PGHS-1 and PGHS-2 are 
virtually superimposable; the backbone atoms demonstrate a meager 0.9-Å root mean 
square deviation of (25). Despite the high degree of sequence homology, key structural 
differences between PGHS-2 and PGHS-1 lead to functional differences between the two 
enzymes.  For example, PGHS-2 (599 amino acids) is 19 amino acids larger than PGHS-
1 (580 amino acids) as the result of an extra 19 amino acids in PGHS-2 located at the C-
terminus of the protein. This short stretch of amino acids direct PGHS-2 to the 
endoplasmic reticulum associated degradation system (ERAD), where proteins that are 
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toxic or misfolded are ubiquitinated and subsequently degraded via the 26 S proteasome 
pathway (43). Thus, PGHS-1, which lacks this sequence has a half-life (t1/2) > 12 hours in 
NIH/3T3 fibroblasts, whereas PGHS-2 has a t1/2 of about 2 hours (43).  PGHS-1 and 
PGHS-2 also differ in their post-translational modifications. PGHS-1 is N-glycosylated at 
three positions, whereas PGHS-2 can be variably glycosylated at two to four positions. 
One of these, Asn-594, is associated with the ERAD degradation pathway discussed 
above. Mutation of this residue to an alanine (Asn594Ala) decreases the turnover of 
PGHS-2 via the ERAD pathway (44). 
PGHS-1 and PGHS-2 also differ in the regulation of their expression.  PGHS-2 is 
undetectable under normal conditions in most tissues, but is inducible by a number of 
stimuli, including, inflammatory cytokines (e.g. TNF, IL-1β), and growth factors (e.g. 
PDGF, EGF) and tumor promoters (e.g. phorbol ester, benzo[α]pyrene) (27,45), implying 
a key role in the mediation of fever and inflammation. PGHS-1 is expressed 
constitutively in most tissues. Thus, PGHS-1 is ascribed the role of homeostatic 
prostanoid generation, such as gastric cytoprotection and platelet aggregation.  However, 
PGHS-2 is also expressed constitutively in the kidney, brain and spinal cord.  
A third important structural and perhaps functional difference between the 
isoforms is that the PGHS-2 COX active site is about 25% larger than PGHS-1’s 
(24,25,46). This difference in size is due to a single amino acid substitution; PGHS-2 has 
a less bulky Val-523 versus an Ile-523 in PGHS-1. This affords a space extending off of 
the AA binding site that is coded in all PGHS-2 genes sequenced to date. This space 
allowed for the development of PGHS-2 selective inhibitors, the diarylheterocycles, 
which were 1000-fold more selective for PGHS-2 than PGHS-1.  By sparing PGHS-1 
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inhibition, the diarylheterocycles had reduced gastrointestinal side effects compared to 
non-selective traditional NSAIDs, but were potent inhibitors of PGHS-2 mediated pain 
and inflammation. Site-directed mutagenesis of Val-523 leading to the elimination of the 
side-pocket leads to a loss of inhibition by the diarylheterocycles. The reverse is true, 
with creation of a side-pocket in PGHS-1 leading to a sensitization to diarylheterocycle 
inhibition (46-49).  
PGHS-1 and PGHS-2 are both acetylated by aspirin at Ser-530 (50,51). Although 
PGHS-1 is rendered inactive by aspirin acetylation, acetylated PGHS-2 can still 
oxygenate AA to form 15(R)-hydroxyeicosatetraenoic acid, instead of PGH2 (52,53). 
Site-directed mutagenesis eliminating the PGHS-2 COX side-pocket abrogates the ability 
of asprin-acetylated PGHS-2 to oxygenate AA(54). This indicates that aspirin-acetylated 
PGHS-2 accommodates AA in its COX active site by taking advantage of the additional 
space afforded by the side-pocket (54). 
An interesting functional difference between PGHS-1 and PGHS-2 is seen in their 
their sensitivity to activation; PGHS-2 is activated by concentrations of peroxide 10-fold 
lower than those required to activate PGHS-1 (35). Although the structural foundation for 
this remarkable difference is not known, it indicates that PGHS-2 can be active at low 
peroxide concentrations while PGHS-1 remains latent, a phenomenon that may provide 
differential control of catalysis between the two isoforms (35).  
 
Prostaglandins 
PGH2 is a substrate for five downstream synthases that lead to the generation of the 
prostanoids, PGE2, PGD2, PGF2α, PGI2, and TxA2  (Figure 6). Prostanoids act in an 
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autocrine and paracrine fashion, through separate G-protein coupled receptors (GPCRs), 
eliciting a broad array of effects that are cell and tissue dependent (Figure 6). A brief 
description of the major in vivo actions of the prostanoids follows. 
 
Pyrexia, Pain and Inflammation 
The role of prostaglandins in effecting pyrexia was discovered when an infusion of a 
PGE2 analog, PGE1, into the third ventricle of the cat brain was shown to cause 
elevations in body temperature(55). PGE2 has been shown to act through four EP 
receptors (EP1-4), in mediating its downstream effects. PGE2, which is the major AA 
oxygenation product, can agonize abundantly expressed EP3 receptors in the organum 
vasculosum lamina terminalis (OVLT) an area connected to the anterior hypothalamus, 
and devoid of the blood-brain barrier (56,57). This area is critical to regulation of the 
body’s temperature set point, and EP3 agonism leads to an elevation in the body’s 
temperature set point. Fever soon ensues, and what is known as the febrile response. A 
key role for PGHS-2 is effecting the febrile response. While PGHS-2 expression in the 
brain is mostly constitutive, endothelia in the brain’s vasculature and glia in the brain can 
be induced to up-regulate PGHS-2 and PGE synthase (PGES) production in response to 
blood-borne pathogens and inflammatory cytokines, leading to the generation of PGE2 
(58-60). Convincing evidence for PGHS-2’s role in mediating pyrexia is the fact that 
PGHS-2 selective inhibitors, such as the diarylheterocylces, are anti-pyretic (61). 
Furthermore, PGHS-2-null and EP3-null mice cannot mount the febrile response in 
response to cytokines or bacterial lipopolysaccharides, while the febrile response remains 
intact in PGHS-1-null mice (56,57,61).  
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Figure 6. Prostanoid biosynthesis, downstream GPCRs and selected effects of GPCR agonism 
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 Following the demonstration that NSAIDs inhibited prostanoid biosynthesis, Sir 
John Vane concluded that the production of PGE2 or a similar prostanoid in the brain was 
responsible for the febrile response. He further proffered that the analgesic action of 
NSAIDs was also through the inhibition of prostanoid production, despite the fact that 
there was direct evidence that local adminstration of prostanoids did not cause much 
more than a “weal and flare”(16). While it may have been difficult to demonstrate that 
prostanoids directly effected pain, he correctly ascribed local inflammation to PGE2, as it 
had been isolated from wound exudate from carrageenan inflammation in the rat (62). 
This said, inflammation usually precedes pain, and it has been recently demonstrated that 
prostanoids, especially PGE2, cause a sensitization of both peripheral and central pain 
pathways (63,64). Tissue damage can cause the release of inflammatory cytokines such 
as TNFα and IL-1β, that cause an induction of PGHS-2 expression which leads to the 
generation of PGE2, eventuating in increased peripheral synaptic excitability and firing 
(64-66). In a feed-forward mechanism, increased peripheral firing, induced by PGE2, 
causes an induction of excitoxicity in upstream neurons in areas critical for the 
modulation of pain; the dorsal root ganglia and the dorsal horn of the spinal cord (64,67). 
This series of events leads to hyperalgesia, which is an increase in the gain in the pain 
system leading to an exaggerated pain response, and allodynia, which is a pain sensation 
in response to non-pain evoking stimuli (63). The involvement of the PGHS pathway in 
the amplification of pain will be revisited in the discussion of the endocannabinoid 
system. 
 PGHS-2 has been found to be elevated in the mucosa of asthmatics, leading to 
exuberant amounts of PGD2 in lung tissue and the pathognomonic hyper-reactive airways 
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upon allergen exposure.  PGD2 agonism at DP1 receptors effects contraction of smooth 
muscle cells found in lung airways leading to the airway constriction characteristic of 
asthma. This is evident in mice lacking the DP1 receptor that are resistant to allergens that 
mediate asthma (68). Unfortunately, NSAIDs do little to ameliorate asthma, and in fact, 
make symptoms worse in 10% of asthmatics (69) . It is accepted that interaction of the 
prostanoid pathway with another AA consuming pathway, the leukotriene pathway, 
explains why diminution of PGD2 levels in the lung does little to prevent asthma (69).  
 
Reproduction 
While the prostanoids were initially discovered via their action on reproductive 
tissue, we are now just now beginning to appreciate the complex role of the prostanoid 
pathway in reproduction. In mammals, PGE2 is important for the effective maintenance 
of pregnancy; in fact, mice lacking the EP2 receptor manifest diminished fertility (70-72). 
While a clear connection between the agonism of EP2 receptors by PGE2 and fertility is 
not as clear, PGE2 is produced in the hypothalamus and can modulate the production of 
the gonadotropin, luteinizing hormone, which surges during the menstrual cycle leading 
to ovulation (70). PGF2α is critical for the birth of live young. Its ability to contract 
uterine tissue was discovered when semen was shown to induce uterine contractions (8). 
PGF2α levels in pregnant women are greatly elevated just prior to parturition and its 
administration to women at the term of their gestation leads to induction of labor (73,74). 
Mice lacking the FP receptor bear defects in parturition (75). The production of PGF2α at 
the term of gestation leads to the dissolution of the corpus luteum, which is critical for the 
maintenance of pregnancy to term. The dissolution of the corpus luteum leads to a drop in 
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progesterone and the induction of the oxytocin receptor in the uterus. This leads to 
increased sensitivity of the uterine myometrium to the induction of contractions in 
response to oxytocin. Interestingly, PGHS-2–null female mice are infertile (76), while 
PGHS-1–null females demonstrate normal fertility.  However, while PGHS-2–null mice 
demonstrate defects in ovulation, fertilization and implantation, PGHS-1–null mice lack 
these defects but exhibit a higher than usual perinatal morbidity (77,78). Thus, a 
simplistic view of the roles of the two isoforms in reproduction is appreciated.  PGHS-2 
is involved in the early events in pregnancy, while PGHS-1 plays a role in later events, 
especially those around parturition. 
 
Cardiovascular and Renal 
The prostanoid pathway’s role in maintenance of vascular homeostasis is widely 
appreciated. This was first evident following the discovery that PGE2 and PGE1 could 
cause platelet aggregation (79-81). It has now been demonstrated that the actions of 
vascular endothelium-derived PGI2 and platelet-generated TxA2 strike a balance between 
vasodilation/anti-thrombosis and vasoconstriction/thrombosis that maintains patency of 
the body’s vasculature under normal conditions. Mice deficient in the TxA2 receptor (TP) 
demonstrate increased bleeding times and cannot induce platelet aggregation in response 
to appropriate agonists (82). However, mice deficient in the PGI2 receptor (IP) do not 
demonstrate any immediate defects in bleeding times; however, vascular endothelial 
damage dramatically increases thrombogenesis (83). Platelets are anuclear cell fragments 
of the hematological precursor cell, the megakaryocyte. Platelets therefore do not posses 
the machinery to express more protein than they already contain. This leads to their 
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relatively short t1/2 of 5-9 days. Furthermore, platelets do not contain any PGHS-2 so 
PGHS-1 is the sole source of the TxA2 generated in platelets. PGI2 is made upon damage 
to vascular endothelium, chiefly from the action of PGHS-2. The finding that un-
challenged PGHS-2–null mice demonstrate no defects in bleeding further supports this. 
The use of controlled release, low-dose aspirin leads to selective and irreversible 
inhibition the PGHS-1 in platelets; this results in inhibition of TxA2 production for the 
life of platelet and systemic anti-thrombosis due to the shift in the vascular prostanoid 
profile, favoring the production of PGI2 over that of TxA2. Controlled release, low-dose 
aspirin is a gold standard for prophylaxis of thrombosis in susceptible cohorts, such as 
those who have suffered myocardial infarction (84,85).  
PGE2 is involved in maintenance of vascular tone related to salt intake (72). EP2–
null animals manifest profound hypertension in response to a high salt diet. This suggests 
that aberrations in PGE2 might be to blame for salt sensitive hypertension (72). 
PGE2 and possibly PGI2 play a role in vascular remodeling at birth. Closure of the 
ductus arteriosus (DA) in a newborn fetus is required to block the shunt between the 
pulmonary artery and the aorta. This shifts oxygenation of blood in the baby from the 
placenta to the lung. Premature closure of the shunt can lead to congestive heart failure, 
and failure to close postpartum leads to mixing of oxygenated and deoxygenated blood, 
and a decreased capacity to effectively oxygenate blood. NSAIDs can be used to initiate 
the closure of the DA or conversely, patency can be maintained by use of PGE1 
(Alprostadil) (86). The role of PGE2 in vascular remodeling is demonstrated by the fact 
that EP4–null mice demonstrate a patent DA at birth (87).   
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While prostanoids have been known to play a major role in renal physiology, 
there has been no real delineation of the exact mechanism by which this occurs.  Their 
importance is highlighted by the roles of vasodilatory PGE2 and PGI2 under conditions of 
compromised renal function as occur in renal insufficiency, glomerular disease, liver 
cirrhosis, and congestive heart failure (88,89). Under these conditions, NSAIDs have 
been shown to cause renal ischemia leading to renal failure by blocking the synthesis of 
the vasodilatory prostanoids, which serve to maintain renal blood flow (88,89). Thus, the 
prostanoid pathway acts along with the renin-angiotensin system in maintaining renal 
physiology especially in the presence of underlying pathology. It is worth mentioning 
that PGHS-2–null mice have renal developmental problems, with kidneys demonstrating 
few, poorly developed nephrons and mesenchyma (76,78,90).  
 
Neoplasia 
The potential role of PGHS in neoplasia was first demonstrated by the finding that 
NSAIDs were chemopreventative in animal models of colon cancer (91,92). These 
findings were extended in humans with the demonstration that sulindac, an NSAID, 
reduced the burden of precancerous polyps in patients with familial adenomatous 
polyposis coli, a genetic condition that invariably leads to colorectal cancer (93,94). 
Retrospective studies on the use of aspirin in a very large cohort (660,000) led to the 
clear demonstration of a link between aspirin use and a decrease in mortality from colon 
cancer (95). Other NSAIDs have also been shown to decrease mortality from colorectal 
cancer (96-98). Furthermore, it has been demonstrated that PGE2 is elevated in colorectal 
tumors and in the urine of cancer patients (99-101). This suggests that the prostanoid 
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pathway in colorectal tumors is deranged, allowing for the production of large amounts of 
PGE2, consistent with the finding of constitutive over-expression of PGHS-2 in these 
tumors (102). PGHS-2 generates PGE2, which has been shown to enhance the growth of 
colorectal cancer cells by promoting angiogenic endothelial cell growth and blood vessel 
formation (103,104). Targeting the overexpression of PGHS-2 in colon cancer led to the 
initiation of clinical trials of PGHS-2 selective inhibitors (COXibs) for the prevention of 
colonic polyp development or recurrence (105-107). The results were as expected; the 
COXibs caused a reduction in colon polyp recurrence of up to 24% (105). As exciting as 
these findings were, they were overshadowed by an almost 2-fold increase in the risk of 
cardiovascular events in the trial participants who were on COXibs, relative to study 
participants on placebo (19). This led to the misconception that COXibs carried an 
increased risk of cardiovascular events over that of non-selective NSAIDs and ultimately 
led to the premature withdrawal of almost all the COXibs on the market. This fanfare was 
short-sighted as it has now been shown that ALL NSAIDs carry as great a risk of 
cardiovascular events as the COXibs (19). 
 
So, despite the wealth of knowledge about the actions of prostanoids, our 
knowledge about their complex interactions under both homeostatic conditions and 
pathology is still incomplete. This has recently come to light with the COXib fiasco, 
where despite attractive hypotheses, it is still not clear why NSAID use leads to increased 
cardiovascular effects(19). 
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Glutathione Peroxidases 
 
Structure and biochemistry 
There are over 30 different mammalian selenoproteins (108). Of these, four are 
glutathione peroxidases (GPxs), which carry out the reduction of peroxides using the  
tripeptide glutathione (GSH, Glu-Cys-Gly) as the reductant (Figure 7).  
 
 
Figure 7. The reduction of a peroxide by glutathione peroxidase 
 
The four mammalian isoforms of glutathione peroxidase are; the classical or cytosolic 
glutathione peroxidase (GPx1 or cGPx), the gastro-intestinal glutathione peroxidase 
(GPx2 or GI-Gpx), the plasma glutathione peroxidase (GPx3 or pGPx) and the 
phospholipid hydroperoxide glutathione peroxidase (GPx4 or PHGPx). Their expression 
is varied and tissue specific, leading to confusion about each isoform’s specific function 
(109). There is general agreement in the field that they serve to protect the cell from 
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oxidant stress. Interestingly, there are several chronic degenerative conditions, such as 
Alzheimer’s and Parkinson’s Diseases, that are associated with depletion of the GPx 
reducant, GSH(110).  
 
GPx1 
GPx1 was the first glutathione peroxidase to be characterized.  Discovered in 
1957, GPx1’s importance in protecting heme in the erythrocyte from oxidative damage 
(111) was quickly recognized, and it has subsequently been shown to be expressed at 
high levels in tissues that have a high rate of peroxide production, such as liver, kidney, 
and lung (109). GPx1 expression has also been shown to follow metabolic activity. In the 
newborn rat lung, GPx1 expression is high, especially following exposure to high oxygen 
tension (112). Interestingly GPx1–null mice develop normally, and only succumb to very 
high level of oxidant stress (113,114). It appears as though the peroxide detoxification 
systems in the cell have evolved redundancies to ensure the cell is protected from oxidant 
stress. Breast, kidney, and prostate cancers demonstrate reduced GPx1 activity (115-118), 
so despite the apparent lack of an overt phenotype in the GPx1–null mouse, loss of GPx1 
functionality is associated with malignancy. Apparently, loss of GPx-1, while not being 
directly causative, is permissive of other processes that have been shown to be important 
for tumorigenesis. These include the association of redox stress with high PGHS activity, 
which as discussed earlier promotes tumor growth and vascularization through the 
production of angiogenic PGE2 (99-101,115). The association of increased redox stress 
with prostaglandin generation is examined as part of this work. 
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GPx2 
GPx2 is expressed exclusively in the gastro-intestinal (GI) system, and is 
restricted to the epithelium (119). It was initially thought to be the first barrier against 
ingested hydroperoxides (119), but has now been shown to associate with the highly 
proliferative cells in GI crypts, where it plays a role in the regeneration of GI epithelium 
(120). Although GPx2 is upregulated in some malignancies, knock-out mice are more 
susceptible to tumors induced by UV- irradiation (121) and a combined GPx1 and GPx2 
knock-out leads to an increased incidence of intestinal tumors (122). In this model, 
GPx2’s role in the development of intestinal tumors was preceded by the development of 
an inflammatory condition (colitis), leading to the supposition that GPx2 plays a role in 
modulating inflammation (122). Transcriptional control of GPx2 expression occurs via 
the Nrf2 pathway, which is activated by xenobiotics and oxidative stress, serving to 
induce several cytoprotective enzymes such as γ-glutamylcysteine synthase (γ- GCS)- the 
enzyme that generates GSH, and heme oxygenase- an enzyme involved in the 
metabolism of heme (123-125). GPx2 has been hypothesized to antagonize PGHS-2-
mediated PGE2 production, and in fact, GPx2 and PGHS-2 are both upregulated in the 
intestinal epithelium of patients with sporadic colorectal cancer (126). Furthermore, 
stable siRNA knock-down of GPx2 in a colorectal cancer cell line enhances PGHS-2 and 
PGE synthase  (PGES) expression. It is noteworthy that PGE2 can act in a paracrine loop, 
inducing PGHS-2 expression (126). While its exact role is still not known, GPx2’s 
importance both in oxidant homeostasis and cancer is now apparent. 
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GPx3  
GPx3 is the most poorly understood glutathione peroxidase. It is found in plasma where 
the low GSH concentrations (30 µM) can only support a limited number of catalytic 
turnovers (127). Its role is therefore unclear. GPx3 is mainly produced in the kidney by 
proximal tube epithelium and parietal cells in Bowman’s capsule (128). Spurring a 
renewed interest in GPx3’s function is the finding that it can use thioredoxin and 
glutaredoxin as reductants, in lieu of GSH (129). This means that the low plasma GSH 
levels might not be limiting to its unknown, specific function. 
 
GPx4 
The phospholipid hydroperoxide glutathione peroxidase is perhaps the most important 
GPx of all four. It is the only one required for life, since homozygous GPx4–null mice are 
embryonic lethal (130). Compared to wild-type littermates, GPx4–null embryos show 
defective gastrulation and almost no indication of the development of ectoderm, 
mesoderm, or endoderm (130). GPx4 was initially discovered as a factor in preventing 
lipid peroxidation (131) and  is strongly associated with the lipid bilayer, congruent with 
its role as the only glutathione peroxidase capable of reducing phospholipid-bound 
hydroperoxides (132-134). Over-expression of GPx4 in rat basophilic leukemia cells is 
protective against oxidative and metabolic stressors, such as t-BOOH, rotenone, and 
potassium cyanide (135). Overexpression of GPx-4 has also been shown to reduce 
apoptotic markers such as mitochondrial cytochrome c release and caspase activation 
(136).  Mice deficient in the enzyme that generates GSH, γ-glutamylcysteine synthase (γ- 
GCS), die at the same stage of development as GPx4 –null embryos, suggesting that 
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GPx4 is perhaps the limiting GSH-utilizing enzyme. (137). Primary embryonic 
fibroblasts from conditional GPx4-null mice demonstrate overt lipid peroxidation, 
compared to wild-type cells, that is associated with a high rate of apoptosis. The lethality 
of the mutation of GPx4 is also associated with the metabolism of AA by enzymes 
known as lipoxygenases (LOX). LOXs are a diverse group of non-heme iron-containing 
enymes that can carry out regio and streospecific oxygenation of FAH such as AA, 
forming hydroperoxyeicosatetraeinoic acid (HpETE). LOXs are not restricted to free 
FAH and can oxygenate phospholipid esterified FAHs (138,139).  In a conditional 
knockout of GPx4, apoptosis is induced by lipid peroxidation that requires the presence 
of functional LOX (110).  Furthermore, specific LOX inhibitors were effective in 
preventing cell death due to GPx4 depletion. Overt lipid peroxidation and the ensuing 
apoptosis in GPx4-null fibroblasts were prevented by lipid-soluble α-tocopherol, while 
water-soluble anti-oxidants could prevent neither lipid peroxidation nor apoptosis. (110).  
Of interest to us, is the fact that GPx4 is involved in the modulation of AA 
metabolism by PGHS (140). As previously discussed, PGHS requires peroxide to activate 
its oxygenase activity. Depletion of GPx4 in human epidermoid carcinoma cells leads to 
massive increases in oxidant stress and a doubling of the metabolism of AA by PGHS 
(140). Conversely, over-expression of GPx4 in rat basophilic leukemia cells leads to a 
four-fold reduction in stimulable PGD2 levels relative to wild-type cells (141). This work 
reveals the most direct connection of a specific GPx to its ability to modulate PGHS 
activity. Previous work had predicted this finding; rudimentary measurements of the 
levels of PGHS activity compared to those of GPx in tissue homogenates demonstrated 
that they were inversely correlated (38).  While this work was conducted before the 
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discovery of PGHS-2 and therefore did not consider the inducibility of PGHS-2, it still 
established a correlation that has held to date. Tissues that generate large quantities of 
prostanoids such as monocytes, possess the least total GPx activity, while those that do 
not generate large amounts of prostanoids, such as the liver, possess the highest total GPx 
activity (38). Furthermore, the ability of GPx to suppress PGHS has been studied 
extensively in vitro. The relationship between PGHS activation and GPx4 is explored 
further in this work. 
The Endocannabinoid System 
 
Historical Overview 
The Cannabis plant is a dioecious, flowering herb, indigenous to central and south Asia. 
Its use, at least for fiber, dates back to 10000 B.C as depicted in this pictogram of two 
hemp plants, under a shelter (Figure 8) (142). The medicinal use of Cannabis in Egypt is 
documented in Eber’s papyrus, dating back to 1500 B.C. (143), but its use in Europe was 
similar as in Asia, mostly for rope making and fabric. Cannabis’ alternative applications 
first started attracting attention when Napoleon’s troops returned from Egypt and 
reported its psychotropic activity; they described it as intoxicating and narcotic (144). 
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Figure 8.  Chinese pictogram of two hemp plants under a shelter, dating back to 
10,000 B.C.  
Soon thereafter, Cannabis extracts were introduced into the medical community and in 
1848, the British Pharmacopoeia heralded its analgesic and antispasmodic activities 
(144).  The active constituent of Cannabis, a terpenoid derivative Δ9-
tetrahydrocannabinol (THC), was finally identified in 1964 (Figure 9) (145). 
 
 
Figure 9.  Cannabis’ primary psychotropic constituent, Δ9-tetrahydrocannabinol 
 
THC’s structure did not hint at any exact mechanism of action, and it was thought 
to modulate membrane fluidity, due to its lipophilic nature.  The generation of analogs of 
THC led to a description of areas of the brain that were receptive of the active 
compounds (146). The cannabinoid receptor (CB1) was finally cloned from rat brain in 
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1990 (147). A second isoform, CB2, that is primarily expressed in the immune system, 
was cloned by sequence homology three years later (148). The search for an endogenous 
ligand for the CB receptors led to the discovery of a lipid, which was identified as an 
ethanolamine amide of AA (arachidonoyl ethanolamine, AEA) (Figure 10) (149). It was 
christened anandamide from the Sanskrit word for bliss, ananda (149). Soon thereafter, 
another endogenously produced lipid CB ligand was discovered. It was a glyceryl ester of 
AA, 2-arachidonoyl glycerol (2-AG) (Figure 10) (150). Although a number of other 
lipids produced in vivo have been shown to agonize CB receptors, AEA and 2-AG remain 
the best understood and most physiologically relevant (144).  
 
 
 
Figure 10.  Structures of the endocannabinoids 
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when neurons fire. This leads to the activation of a phospholipase D that cleaves the 
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phosphatidylcholine to the head group of phosphatidylethanolamine (Figure 11) (144). 
NAT is inactive in the absence of Ca2+, and increasing concentrations of Ca2+ during 
synaptic transmission have been shown to activate latent NAT. The activity of NAT is 
enhanced upon phosphorylation by protein kinase A. Protein kinase A’s activity, in turn, 
is regulated by levels of the second messenger cyclic AMP (cAMP) (152). Therefore, 
despite low basal amounts of NArPE in the brain (20-40 pmol/g), continuous synaptic 
transmission ensures that Ca2+ levels stay high enough to maintain NAT activity (144). 
Upon its generation in neurons, AEA passively diffuses through the post-synaptic cell 
membrane owing to its lipophilic nature, exposing it to its intracellular catabolic enzymes 
(153).  
AEA is also specifically trafficked by a transporter, modulation of which has been 
shown to vary intracellular AEA levels (154). Upon entry into the cell, AEA is subject to 
hydrolysis by a membrane-bound serine hydrolase, fatty acid amide hydrolase (FAAH) 
(155).  Hydrolysis of AEA leads to the formation of AA and ethanolamine and the 
termination of endocannabinoid signaling. AEA is also subject to oxidative metabolism 
by PGHS, LOXs, and cytochrome P450 enzymes (CYPs) (156). The oxygenation of 
AEA by PGHS-2 leads to the formation of PGE2-EA at a rate comparable to that of PGE2 
from AA, but with AEA’s Km for PGHS-2 about 4-fold higher than AA’s (157). PGH2-
EA is as an efficient substrate for the majority of the downstream synthases responsible 
for prostaglandin synthesis, save for TxA2 synthase (Figure 12). Interestingly, AEA is an 
extremely poor substrate for PGHS-1, suggesting that the oxygenation of neutral AA 
derivatives is a possible distinction in function between PGHS-1 and PGHS-2. TxA2 
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demonstrates substrate specificity that is associated with the carboxy terminus of PGH2, 
indicating a neutral amide like PGH2-EA would form a poor substrate (158). 
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Figure 11. Biosynthesis of Anandamide 
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While it is interesting that AEA is substrate for PGHS-2, AEA is only present at 
very low levels, even in the presence of a stimulus, peaking in the nanomolar range, 
while its Km for PGHS-2 is 26 µM (159,160). It remains to be seen whether the 
oxygenation of AEA by PGHS-2 is physiologically relevant. The generation of the 
FAAH- null mouse has revealed the AEA levels are tightly regulated by this enzyme, 
with the mice showing high sensitivity to administered AEA (161). This has thus far 
established FAAH as the chief metabolizing enzyme for AEA. 
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Figure 12. Oxidative Metabolism of AEA by PGHS-2 
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2-AG Biosynthesis and Metabolism 
2-AG is at the crossroads of multiple metabolic pathways, which has hampered 
efforts to study its biosynthesis (144). Like AEA, the biosythesis of 2-AG is initiated by 
increasing Ca2+ levels. Increased intracellular Ca2+ activates phospholipase C (PLC) 
which hydrolyzes phosphatidyl inositol (PI), liberating 1,2 diacylglycerol (DAG). DAG 
is then hydrolyzed to 2-AG, by DAG lipase (DGL) (Figure 13) (162). An alternative 
pathway for the generation of 2-AG begins with the generation of 2-Arachidonoyl 
lysophospholipid, mediated by phospholipase A1(163,164). 2-rachidonoyl 
lysophospholipid may be hydrolyzed by lyso PLC, forming 2-AG (Figure 13). There is 
no direct evidence for this second proposed pathway; however PLA A1 is highly 
expressed in the brain, making this pathway possible (162,163).   
Upon its post-synaptic release, 2-AG can passively diffuse into the intracellular 
compartment, or be rapidly and selectively transported by carrier systems present in 
neurons (153,154). Once in the intracellular compartment, 2-AG is subject to various 
metabolic pathways. Similar to AEA, 2-AG is subject to hydrolytic inactivation, 
generating AA and glycerol, primarily by a serine hydrolase known as monoacylglycerol 
lipase (MAGL)(165). MAGL is widely distributed in the central nervous system and its 
activity leads to a termination of 2-AG mediated endocannabinoid signaling (166). This 
has made it a suitable pharmacological target, as a tool to evaluate the role of the 
endocannabinoid system. Indeed, Long et al. (2009) stepped up to this challenge with the 
development of a powerful new inhibitor design tool, activity based protein profiling 
(ABPP) (167), which allowed them to generate potent specific inhibitors. Their best 
compound, JZL184, selectively inhibits MAGL with an IC50 of 8 nM and inhibits up to 
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85% of total rat brain hydrolysis of 2-AG. The rest of the hydrolysis of 2-AG is mediated 
by FAAH and other serine hydrolases such as ABHD6 (168). JZL184 also inhibits 
FAAH, with an IC50 of 4 µM, increasing its utility in dissection of the endocannabinoid 
signaling pathway (169). The inhibition of 2-AG hydrolysis by JZL184 in mice leads to 
an 8-fold increase in 2-AG levels and recapitulates CB1-mediated behavioral and 
physiological effects, including analgesia, hypothermia, and hypomotility (170). The 
ability to pharmacologically modulate 2-AG levels has opened avenues of research for 
applications in a number of neurological and physiologic disorders where 2-AG-mediated 
endocannabinoid signaling has been shown to be important, such as pain, depression, and 
obesity. Recently, it has been shown that aggressive cancers of the skin (melanoma), 
breast, and ovaries overexpress MAGL and hijack this pathway, to generate strongly pro-
tumorigenic terminal free fatty acid metabolites like PGE2 and lysophosphatidic acid. 
Pharmacologic inhibition of MAGL with JZL184 or siRNA-mediated depletion of 
MAGL led to a loss of aggressiveness in cultured melanoma, breast, and ovarian cancer 
cells lines, indicating that MAGL inhibitors might have an application in cancer 
treatment (171,172). 
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Figure 13. Biosynthesis of 2-arachidonoyl glycerol 
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2-AG is also subject to oxidative metabolism by the same spectrum of oxygenases 
that metabolize AEA. Action of human 15-lipoxygenase (15-LOX) on 2-AG generates 
15-hydroxyeicosatetraeinoic acid glyceryl ester (15-HETE-G) which is a potent PPARα 
agonist (173). The oxygenation of 2-AG by PGHS-2 is as efficient as that of AA by 
hPGHS-2, in vitro (174). In cell culture, the action of PGHS-2 on 2-AG leads to virtually 
the same array of prostanoids that are generated from AA, known as prostaglandin 
glyceryl esters (PG-Gs), and similar to PGH2-EA, PGH2-G is a poor substrate for TxA2 
synthase (Figure 14)(175). Like AEA, 2-AG is an extremely poor substrate for PGHS-1, 
suggesting that the oxygenation of neutral AA derivatives is a possible distinction in 
function between PGHS-1 and PGHS-2. TxA2 demonstrates substrate specificity that is 
associated with the carboxy terminus of PGH2, indicating a neutral ester like PGH2-G 
would form a poor substrate (158). Mouse peritoneal macrophages pre-treated with the 
inflammatory stimulus LPS and followed by zymosan phagocytosis lead to the formation 
of PGE2-G and PGI2-G (176). While the levels of 2-AG released in response to agonist 
were only 10 fold lower than those of AA, the ratio of the total PGs:PG-Gs detected was 
1000:1, indicating that PG-Gs were formed inefficiently (177). Determinants of the 
inefficient oxygenation of 2-AG are examined in this work. 
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Figure 14. Oxidative Metabolism of 2-AG by PGHS-2 
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PGE2-G has a t1/2 of 14 seconds in rat plasma and 7 minutes in human plasma (177). The 
rapid hydrolysis of PG-Gs has hampered the validation of the PGHS-2/2-AG pathway; however, 
recent exciting work has demonstrated that the PGHS-2/2AG pathway is worth considering. 
PGE2-G has been shown to act at a yet to be identified unique receptor, independent of the 
traditional PG receptors, mediating Ca2+ mobilization in RAW264.7 macrophages and inducing 
aberrant pain sensations and (allodynia) and increased sensitivity to pain (hyperalgesia) in rats 
(178,179). Further validation of this pathway is described herein. 
 
Cannabinoid Signaling and Biology 
As mentioned before, two-cannabinoid receptors have been cloned. The CB1 receptor is 
the most abundant GPCR in the mammalian brain, highlighting the importance of 
endocannabinoid signaling. CB1 receptor expression primarily in the hippocampus, basal 
ganglia, cerebellum, brain stem, spinal cord, and dorsal root ganglia (180) explains the action of 
CB1-mediated signaling. Furthermore, the four symptoms defining cannabinoid intoxication in 
rat models, hypothermia, hypomobility, and analgesia, are absent in CB1 –null mice (181). The 
pertussis toxin-sensitive Gi/o CB1 mediates these effects by inhibiting voltage gated N- and P/Q 
type voltage-activated Ca2+ channels and K+ channels. The β-γ subunits of the Gi/o bind to both 
the Ca2+ and K+ channels and depress the signaling at GABA and glutaminergic synapses in the 
CNS (144). This depressive effect on synaptic transmission is the hallmark of cannabinoid 
signaling. The CB2 receptor is expressed in immune cells, such as macrophages and B-cells 
(148). The role of endocannabinoid signaling in the immune system has not been adequately 
explored. This is reflected in the limited number of reports of CB2-mediated actions in the 
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immune system. However, 2-AG has been shown to posses anti-inflammatory activity and can 
alter cytokine production (182). 
While 2-AG is a full agonist at both CB1 and CB2 receptors (183,184), AEA is only a 
partial CB1 receptor agonist and does not agonise the CB2 receptor at all (185,186). In addition to 
being an endocannabinoid, AEA also binds and activates the transient receptor potential 
vanilloid receptor (TRPV1), which was discovered for its sensitivity to capsaicin.  AEA binding 
to the TRPV1 receptor in the nerves of blood vessel walls elicits vasodilation (187). TRPV1 is 
expressed in the CNS and peripheral nervous system (PNS), where its role is thought to be the 
detection of noxious stimuli such as heat and low pH (188). Thus AEA is also considered an 
endovanilloid. For the rest of the discussion and for the sake of pertinence to the work presented 
herein, we will focus our attention on 2-AG which is considered a pure endocannbinoid and is 
more abundant and ubiquitous across the CNS and PNS with brief mention of significant AEA 
biology in the literature (144). 
 
The physiological actions of AEA and 2-AG 
The involvement of the endocannabinoid system in the modulation of pain is one of the 
most attractive features of this pathway. The potential medical applications are evident in the 
embracing of medicinal marijuana by a number of states in the U.S. and across the world. 
Current treatment modalities, primarily with opiates, are habit forming and can be dangerous, 
whereas cannabinoid-based therapies bear promise due to their safety and low potential for habit 
formation. There are a number of issues associated with marijuana use, such as the exact 
chemical composition of Cannabis extracts, which can vary by strain and plant, and the health 
risks associated with the chief mode of administration, smoking. The realization that modulation 
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of the endogenous cannabinoid system could mediate the same effects as Cannabis- bypassing 
the socioeconomic, legal issues, and smoking health risk associated with Cannabis consumption- 
is exciting and warrants fervent investigation (189). 
 
Pain and Inflammation 
In the brain, endocannabinoids have been shown to tonically modulate neuronal 
transmission in the rostral vental medulla (RVM), the periaqueductal grey, and the spinal 
trigeminal areas critically involved in the promotion of central analgesia (190-192). Supporting 
the importance of these areas in the modulation of pain is the fact that localized treatment with a 
CB1 receptor antagonist leads to the induction of hyperalgesia, in an opioid–independent manner. 
Noxious and painful stimuli from the periphery create neuronal hyperexcitability in the dorsal 
horn of the spinal cord.  This hyperexcitability leads to increased glutaminergic signaling and 
excitotoxicity and induces the expression of PGHS-2 (67). Recent work has demonstrated that 
spinally applied PGHS-2 inhibitors prevent this hyperexcitability by preserving the levels of 
neuronal 2-AG leading to analgesia (193). This suggests that PGHS-2-dependent metabolism of 
2-AG may play an important role in the regulation of nociception. Interestingly, intraperitoneally 
injected 2-AG has been shown to prevent the induction of PGHS-2 by inflammatory (LPS) and 
excitotoxic stimuli (glutamate) in the mouse hippocampus, in a dose-dependent manner (67).  
These actions, which were absent in CB1–null mice and in the face of CB1 antagonism, were 
mediated by β-γ subunits associated with CB1-activated G proteins.  2-AG-mediated signaling in 
this model attenuated phosphorylation of p38 MAP kinase and NF-κB leading to decreased 
expression of PGHS-2. The inhibition of hydrolysis of endogenously produced 2-AG using 
MAGL inhibitors recapitulated the effects of exogenous 2-AG, indicating that preservation of 
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endogenous levels of 2-AG can prevent the induction of PGHS-2 in the hippocampus, even in 
the presence of inflammatory insult (67). Lending credence to the PGHS-2/2AG axis in pain-
related signaling is the finding that PGE2-G elicits neuronal hyperexcitability that is associated 
with allodynia and hyperalgesia (67,179). This has made understanding and targeting the PGHS-
2/2-AG axis an important avenue for inquiry and is part of the work presented herein. 
 
Addiction and Food Intake 
 
The endocannabinoids have also been shown to play a role in reward based addictive 
disorders and behaviors such as obesity, tobacco and, alcohol abuse (144). The reward pathway 
in the nucleus accumbens (NA) is critical for habit formation, and has been shown to be involved 
in an array of reward-based activities. Recently, levels of 2-AG in the NA have been shown to be 
elevated in rats self-administering ethanol, in a dose-dependent manner (194). Supporting a role 
for 2-AG in ethanol addiction is the fact that rats chronically self-administering ethanol 
demonstrated potentiated increases in 2-AG levels in the NA of these rats upon each instance of 
ethanol consumption (195). Antagonism of the CB1 receptor using SR141716 (Rimonabant) led 
to a reduction in self-administration of ethanol in chronically self-adminstering rats. This was the 
first indication that modulation of cannabinoid signaling could abate alcohol addiction. Similar 
effects have been reported for heroin abuse, also associated with the NA-associated reward 
pathway (194).  Smoking and eating addiction are also encoded in the same NA dependent 
pathways through which ethanol and narcotic addiction are mediated. Interestingly, in 2001, the 
hormone leptin was shown to reduce hypothalamic levels of 2-AG and AEA, in a dose-
dependent manner (196). Leptin is a key modulator of nutritional status and food intake, and its 
actions lead to reduced food intake. Leptin–null mice (db/db) which are obese, demonstrate 
significantly elevated levels of 2-AG and AEA in the hypothalamus. Similar to the action of 
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rimonabant on ethanol self-adminstration, rimonabant led to reduced food intake and significant 
weight loss in db/db mice, relative to vehicle treated mice (196). These findings led to the 
institution of clinical trials for rimonabant for the treatment of obesity, along with a hypocaloric 
diet and exercise. Cohorts in the rimonabant phase II clinical trial demonstrated weigh loss 
greater than four-fold over those on placebo (4.5 Kg- rimonabant versus 1 Kg – placebo) (144). 
Furthermore, cohorts in the trial on rimonabant had significant lowering of fasting blood glucose 
and triglycerides and an increase in HDL cholesterol; leading to a reduction in cardiovascular 
risk factors in trial participants (197,198). This led to separate clinical trials, to evaluate the 
ability of CB1 antagonism to protect from cardiovascular effects resulting from elevated 
triglycerides and cholesterol (199). Unfortunately, rimonabant was withdrawn from the European 
market in early 2009, citing the increased incidence of suicide among patients taking the drug 
(200).  All the current rimonabant trials have also been halted due to the same safety concerns 
(199).  Despite being heralded as a miracle drug, the future of CB1 antagonism comes into 
question as a result of our poor understanding of the role of the endocannabinoid system in 
mood.  
So far, the only cannabinoid approved by the FDA is synthetic THC, Marinol, which is 
indicated for appetite stimulation (orixogenia) in treating anorexia associated with AIDS and in 
the treatment of nausea associated with chemotherapy.  
 
Motor function 
Endocannabinoids have also been shown to play an important role in locomotion.  The CB1 
receptor is highly expressed in the basal ganglia, an area in the forebrain that plays a critical role 
in motor behavior (144).  The actions of endocannabinoids in the basal ganglia are mediated by 
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the inhibition of the release of the neurotransmitter GABA.  This eventuates in a dimunition of 
dopaminergic signaling, suppressing motor activity (201). These findings indicate that the 
endocannabinoid system may play an important role in debilitating diseases caused by 
dysfunctional dopaminergic signaling such as Parkinson’s and Alzheimers diseases. Further 
work is needed to determine the potential of endocannabinoid modulation in the mitigation of 
these debilitating conditions. 
	   48	  
 
Dissertation Aims 
 
The research described herein encompasses efforts to determine the substrate specific 
determinants of the endocannabinoid 2-AG’s oxygenation by PGHS-2 in vitro and ex vivo. 
Oxidative metabolism of 2-AG by PGHS-2 has been recognized as a pathway for the creation of 
novel prostaglanoid ligands that have unique actions in modulating pain and lead to termination 
of 2-AG-mediated analgesia. These efforts were prompted by findings indicating that factors not 
reflected in steady state parameters may govern the metabolism of 2-AG in the cellular milieu. 
Importantly, the interaction of 2-AG-derived peroxides with PGHSs has not been evaluated. 
These are described in Chapter II; here I undertook an exhaustive study of the disposition of 2-
AG derived hydroperoxides as POX substrates and activators of PGHSs’ oxygenase 
functionality, compared to AA derived hydroperoxides. Further than this, I determined the 
peroxide requirements for activation of PGHS-2 mediated 2-AG oxygenation, relative to AA. As 
an extension of the findings in Chapter II, the ex vivo determinants of 2-AG oxygenation will be 
presented in Chapter III, here I demonstrate that the factors determined in Chapter II may hold 
true in the cellular environment. Chapter IV will highlight my efforts to apply the findings 
presented in the preceding chapters; with the preliminary development of substrate-selective 
inhibitors of PGHS-2-mediated 2-AG oxygenation. Finally, Chapter V will describe the 
development of a robust new screening platform for the development of agents targeting the 
metabolism of AEA and 2-AG by PGHS-2, in a neuronal context.  
  In total, the results presented here provide new information on the determinants of 2-AG 
oxygenation by PGHS-2 and present a case for the relevance of this pathway in endocannabinoid 
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metabolism and foray into the pharmacological modulation of this pathway. The implications of 
these findings will be discussed in Chapter VI.  
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CHAPTER II 
 
 
 IN VITRO DETERMINANTS OF PGHS-2 MEDIATED OXYGENATION OF THE 
ENDOCANNABINOID 2-ARACHIDONOYL GLYCEROL 
 
Introduction 
Prostaglandin H Synthases (PGHSs) catalyze the first two steps in the biosynthesis of 
prostaglandins (PGs), a class of bioactive lipids that regulate a broad range of physiological 
responses. The cyclooxygenase activity oxygenates arachidonic acid (AA) (22) to the 
hydroperoxy endoperoxide, PGG2, and the peroxidase activity reduces PGG2 to PGH2 (Figure 1). 
 
 
Figure 1. Fatty acyl substrate (FAH) oxygenation by PGHS-2 
 
 The two isoforms of PGHS - PGHS-1 and PGHS-2 - are distinguished by different 
patterns of expression. In general, PGHS-1 is constitutively expressed in most tissues suggesting 
a homeostatic role, whereas PGHS-2 is inducible by a variety of inflammatory and proliferative 
stimuli (cytokines, bacterial lipopolysaccharide, growth factors, and tumor promoters), consistent 
with a role for PGs in inflammation and carcinogenesis (27). In addition to differences in 
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regulation, PGHS enzymes exhibit biochemical differences related to their structures. These 
include the increased sensitivity of PGHS-2 to peroxide activation (35) and the presence of a 
sequence in PGHS-2 that renders it susceptible to cellular proteolysis (202).  PGHS-2 also 
displays broader substrate specificity than PGHS-1. For example, it oxygenates ester and amide 
derivatives of AA much more efficiently than PGHS-1(202). 2-Arachidonoylglycerol (2-AG) 
and arachidonoylethanolamide (AEA) are of particular interest as PGHS-2 substrates because 
they occur in human tissue and are endogenous ligands for the cannabinoid receptors (CB1 and 
CB2) (Figure 2)(149,159). 
 
Figure 2.  Structures of the endocannabinoids 
 
PGHS-2-dependent oxygenation of 2-AG yields the glyceryl ester of PGH2 (PGH2-G). 
PGH2-G is converted to a similar array of prostanoids as PGH2 with the exception of its poor 
conversion to TxA2-G (175). Murine resident peritoneal macrophages stimulated with an 
inflammatory agonist (zymosan) produce both PGE2-G and PGI2-G (203), and PGD2-G 
formation is elicited from the RAW264.7 macrophage-like cell line upon pretreatment with LPS 
and IFNγ followed by ionomycin (175).  PGE2-G has been isolated from rat footpads in the 
presence and absence of an inflammatory stimulus (179).  Thus, PG-Gs are produced by intact 
cells treated with a variety of stimuli and are present in vivo. The physiological relevance of 
PGHS-2-dependent 2-AG oxygenation is the subject of ongoing investigation. The kcats for 
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oxygenation of AA and 2-AG by hPGHS-2 are comparable, whereas the kcat for oxygenation of 
AA by mPGHS-2 is approximately twice that of 2-AG (174). An important property of 
derivatives of 2-AG that has not been explored is the ability of glyceryl-hydroperoxides such as 
PGG2-G, to interact with the peroxidase activity of PGHS, either as substrates for peroxidatic 
reduction or as activators of cyclooxygenase activity (Figure 3).  
 
Figure 3.  Interaction of the POX active site and the COX active site 
 
Purified PGHS enzymes are inactive as oxygenases and require hydroperoxide-dependent 
activation to become functional. Fatty acyl hydroperoxides, PG hydroperoxides, or peroxynitrite 
react with the heme prosthetic group (Figure 3) to produce a ferryl-oxo complex that oxidizes 
Tyr-385 in the oxygenase active site to produce a tyrosyl radical (Figure 3); the tyrosyl radical 
oxidizes the fatty acyl substrate (27).  
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We have undertaken a study of the ability of glyceryl hydroperoxides compared to fatty 
acid hydroperoxides to serve as substrates for the peroxidase activity of PGHS-1 and PGHS-2, 
and to activate oxygenation by both enzymes. We also investigated the peroxide-dependent 
activation of AA and 2-AG oxygenation by PGHS-2, by conducting experiments that created 
decreased peroxide tone. The results reveal a major difference in the sensitivity of PGHS-2 with 
respect to the oxygenation of the two substrates i.e., the concentration of peroxide required to 
activate the cyclooxygenase functionality. This concentration, coined Kp (39), is 4-fold higher 
for 2-AG than AA with hPGHS-2. Altogether, these results indicate that the peroxidase active 
site may represent an important site of the regulation and pharmacologic modulation of PGHS-2 
oxygenation of 2-AG. The development of POX inhibitors is described in Chapter IV.	  
 
Experimental Procedures 
Materials - AA, 2-AG, and hematin were obtained from Nu Chek Prep (Elysian, MN), 
Cayman Chemicals (Ann Arbor, MI), and Frontier Scientific (Logan, UT), respectively. All 
other reagents were from Sigma-Aldrich (St. Louis, MO). Peroxide-free AA and 2-AG were 
prepared and confirmed to be free of peroxides as described (204,205). 
Enzymes - Purified bovine erythrocyte glutathione peroxidase (GPx) and purified S. 
cerevesiae glutathione reductase (GSSG reductase) were obtained from Sigma-Aldrich (St. 
Louis, MO). Purified soybean 15-LOX was from Cayman Chemicals (Ann Arbor, MI). hPGHS-
2 and mPGHS-2 were expressed and purified as described (206). Site directed mutagenesis to 
generate H388Y mPGHS-2 and subsequent expression and purification were performed as 
published (34). oPGHS-1 was purified from ram seminal vesicles (Oxford Biomedical Research, 
Oxford, MI), as previously described (207).  The specific activities of hPGHS-2 and mPGHS-2 
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were both 62.5 µM AA per µM enzyme per minute; oPGHS-1 was 325 µM AA per µM enzyme 
per minute. H388Y mPGHS-2’s specific activity was 31.3 µM AA per µM enzyme per minute. 
Chemistry - 15-HpETE was generated with 40% yield as determined by UV spectroscopy 
(236 nm) using the molar absorptivity of conjugated dienes (ε236 = 29,500 M-1.cm-1) (208). 15-
HpETE-G was generated as described (173) with minor modifications. Briefly, to 200 mL of 
oxygen-saturated 100 mM sodium borate buffer (pH 9.0) was added 750,000 U/mL purified 
soybean 15-lipoxygenase. 2-AG (25 mg in 2 mL acetonitrile) was added to the buffer with 
continued perfusion of O2 over the surface of the buffer and stirring. An aliquot of the reaction 
mixture was monitored by UV spectroscopy (236 nm) until no further increase in absorbance 
was evident (~10 minutes). The reaction mixture was extracted twice with 200 mL of diethyl 
ether, and the combined organic layers were dried using MgSO4, filtered, and concentrated under 
vacuum. The residue was resuspended in acetonitrile and filtered over glass wool. 15-HpETE-G 
was generated with 30% yield and was determined using UV spectroscopy (236 nm). Purity was 
determined by HPLC/UV to be ≥ 95%.  
Hydroperoxide regiochemistry of 15-HpETE and 15-HpETE-G were confirmed by diagnostic 
fragmentation following collision-induced dissociation (CID) under the following liquid 
chromatography-electrospray ionization/tandem mass spectrometry (LC-ESI/MS/MS) 
conditions: a Phenomenex Luna C18 column  (100 mm × 2.0 mm, 3 µm) was held at 40°C and 
eluted with 40% A (5 mM NH4OAc in H2O): 60% B (5 mM NH4OAc in 90% CH3CN) at 0.3 
mL/min. Mass spectra were obtained on a ThermoFinnigan Quantum triple-quadrupole 
instrument equipped with an electrospray source and operated in negative ion mode for 15-
HpETE (ESI-MS m/z calculated for C20H32O4 (M-), 335.2; found 335.1) and in positive-ion mode 
for 15-HpETE-G (ESI-MS m/z calculated for C23H38O6 (M+NH4+), 428.3; found 428.1) 
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(ThermoFinnigan, San Jose, CA). Hydroperoxide regiochemistry of 15-HpETE and 15-HpETE-
G were also confirmed by 1H NMR.  
 
15-HpETE 1H NMR at 500 MHz (CDCl3)-	  δ	  6.58-6.63 (dd, 1H, J = 11.1, 15.3 Hz CH), 5.98-
6.02(t, 1H, J = 10.9 Hz CH), 5.56-5.61 (dd, 1H, J = 7.85, 15.3 Hz CH), 5.32-5.48 (m, 5H, 5 x 
CH), 4.39-4.43 (m, 1H, CH), 2.89-3.04 (m, 2H, CH2), 2.77-2.86 (m, 2H, CH2), 2.35-2.38 (m, 2H, 
CH2), 2.10-2.15 (m, 2H, CH2), 1.66-1.75 (m, 2H, CH2), 1.46-1.53 (m, 2H, CH2), 1.23-1.38 (m, 
6H, 3 x CH2), 0.85-0.88 (t, 3H, J = 6.85 Hz CH3)  
 
15-HpETE-G 1H NMR at 500 MHz (CDCl3)- δ	  6.58-6.63 (dd, 1H, J = 11.1, 15.3 Hz CH), 5.98-
6.02 (t, 1H, J = 10.9 Hz CH), 5.56-5.61(dd, 1H, J = 7.85, 15.3 Hz CH), 5.32-5.48 (m, 5H, 5 x 
CH), 4.38-4.42(m, 1H, CH), 4.28-4.32(t, 1H, J = 8.6 Hz CH), 4.09-4.26 (m, 1H, CH), 3.70-3.72 
(m, 1H, CH), 3.60-3.63 (m, 1H, CH), 2.89-3.04 (m, 2H, CH2), 2.77-2.86 (m, 2H, CH2), 2.35-2.38 
(m, 2H, CH2), 2.10-2.15 (m, 2H, CH2), 1.66-1.75 (m, 2H, CH2), 1.46-1.53 (m, 2H, CH2), 1.23-
1.38 (m, 6H, 3 x CH2), 0.85-0.88 (t, 3H, J = 6.85 Hz CH3). 
Detection of endoperoxide intermediates of PGHS synthase action - PGH2, PGG2, PGH2-
G and PGG2-G levels were determined from reactions of hPGHS-2 as follows. hPGHS-2 (400 
nM) was reconstituted with an equivalent of hematin and incubated in 600 µL of 100 mM Tris-
HCl, pH 8.0 with 500 µM phenol at 25° C. Substrate (AA or 2-AG) was added to a final 
concentration of 50 µM.  Reactions were quenched by addition of 600 µL of fresh anhydrous 
diethyl ether, vortexed for 10 seconds, and centrifuged at ~5000 RCF for 45 seconds. Ethereal 
fractions were removed and evaporated to dryness under a gentle stream of argon. Analytes were 
reconstituted in 300 µL acetonitrile:water (50:50 v:v) and analyzed immediately. LC/MS was 
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conducted as follows: Gradient elution [0% A (5 mM NH4OAc in H2O, pH 3.3) linearly to 60% 
B (5 mM NH4OAc in 90% CH3CN] at 0.3 mL/min was carried out on a Waters Acquity UPLC 
BEH C18 column  (100 mm × 2.1 mm, 1.7 µm). Mass spectra were obtained on a 
ThermoFinnigan Quantum triple-quadrupole instrument equipped with an electrospray source 
and operated in positive ion mode with selective reaction monitoring. Quadrupoles 1 and 3 were 
set to the same mass for each analyte (ESI-MS m/z for PGH2 – 370.00 (M+NH4+), PGG2 –386.00 
(M+NH4+), PGH2-G – 444.00 (M+NH4+) and PGG2-G – 460.00 (M+NH4+). 
O2 uptake assay for the COX activity of PGHS - For determination of cyclooxygenase 
activity, pure PGHS protein (100 nM - 400 nM) was reconstituted with hematin and incubated in 
a 600 µL thermostatted cuvette, at 37°C, in 100 mM Tris-HCL, pH 8.0 with 500 µM phenol. 
Peroxide-free substrate was prepared and confirmed to be free of peroxides as described 
(204,205). Substrate was added to a final concentration of 50 µM. Activity was monitored using 
an FO125T Instech fiber optic oxygen probe, connected to an Instech Model 210 fiber optic 
oxygen monitor controlled with OOISensors software (Plymouth Meeting, PA). To test the effect 
of 15-HpETE and 15-HpETE-G in stimulating the turnover of 2-AG by H338Y mPGHS-2, either 
peroxide was added along with substrate to the final desired concentration. 
LC/MS assay for COX activity and inhibition - Hematin-reconstituted PGHS-2 was 
incubated with inhibitor (0.25-50 µM) for 15 min at 37°C prior to the addition of 50 µM 
substrate (AA or 2-AG). The reaction was quenched after 30 seconds with ethyl acetate 
containing 0.5% acetic acid and deuterated internal standards.  The organic layer was extracted 
and evaporated under nitrogen to near-dryness. The residue was resuspended in 50:50 
methanol:water and product formation was monitored using LC-MS/MS. Products were 
separated on a Luna C18(2) column (5.0 cm x 0.2 cm, 3 µm) using an isocratic elution consisting 
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of 65% 5 mM ammonium acetate, pH 3.5 and 35% acetonitrile at a flow rate of 0.375 mL/min. 
The triple-quadrupole mass spectrometer was operated in positive ion mode using electrospray 
ionization using selective reaction monitoring to detect PGs and PG-Gs.  The following 
transitions were monitored: for PGE2/D2 m/z (M+NH4+), 370317, for PGE2/D2-d4 m/z 
(M+NH4+) 374321, for PGE2/D2-G m/z (M+NH4+) 444391 and for PGE2/D2-G-d5 m/z 
(M+NH4+) 449396. Products are quantitated as the ratio of the area of the peak to its 
corresponding internal standard and normalized to a DMSO control. 
 Spectrophotometric assay for peroxidase activity of PGHS - oPGHS-1, hPGHS-2, or 
mPGHS-2 (46 nM) was reconstituted with a one-half equivalent of hematin in 80 mM Tris-HCL 
buffer (pH 8.0) containing 1 mM ABTS (2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) 
and incubated for 1 minute. The mixture was added to a quartz cuvette, and stirred continuously 
at 25° C. 15-HpETE or 15-HpETE-G in acetonitrile was added to desired concentrations (78 nM-
50 µM).  The concentration of acetonitrile was maintained constant for all samples during a 
given experiment and never exceeded 5% of the total reaction volume (2 mL). The reaction was 
monitored via UV spectroscopy (417 nm) for the formation of the ABTS+. radical. The early 
linear portions of the reaction curves were used to determine initial reaction rates, at the various 
substrate concentrations (78 nM - 50 µM). Plots of initial rates versus substrate concentration 
were fit to the Michaelis-Menten equation by nonlinear regression analysis (Prism version 4.0).  
 GPx activity – GPx activity was determined as described (209). Briefly, varying 
concentrations of 15-HpETE or 15-HpETE-G (78 nM-50 µM) were added to a mixture of 0.25 
units of GPx, 1 mM GSH, 1 unit GSSG reductase, and 250 µM NADPH in 100 mM sodium 
phosphate buffer (pH 8.0) at 37°C. The oxidation of NADPH was monitored via UV 
spectroscopy (340 nm). The early linear portions of the reaction curves were used to determine 
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initial reaction rates, and the data were fit to the Michaelis-Menten equation via non-linear 
regression analysis (Prism version 4.0). One unit of GPx catalyzes the oxidation by H2O2 of 1.0 
µM of reduced glutathione (GSH) to oxidized glutathione (GSSG) per minute at pH 7.0 and 25 
°C. One unit of GSSG reductase will reduce 1.0 µM of GSSG per minute at pH 7.6 at 25 °C. 
Activation of cyanide-inhibited oPGHS-1 and mPGHS-2 by 15-HpETE and 15-HpETE-G 
– Activation of PGHS enzymes by hydroperoxides was determined through the ability of the 
hydroperoxide to reduce the NaCN-induced lag phase in the cyclooxygenase reaction (41). The 
standard PGHS activity assay above was modified to include 250 mM NaCN in the buffer. 
Peroxide-free AA along with varying concentrations of either 15-HpETE or 15-HpETE-G (15.6 
nM- 1 µM) was added to the cuvette. Activity was monitored as above, with maximal rate 
determined by taking the first derivative of the reaction trajectory. Lag time (time to maximal 
rate) was determined for each concentration of peroxide (Prism version 4.0), for both oPGHS-1 
and mPGHS-2, and plotted against the concentration of peroxide used.  Statistical significance 
was determined using the Student’s t-test (un-paired, two-tailed) using Prism (version 4.0) 
software. 
GPx-mediated suppression of AA and 2-AG oxygenation by hPGHS-2 and mPGHS-2 - 
The standard PGHS activity assay was modified to include 1 mM GSH and varying 
concentrations of GPx (20 U- 160 U). Activity was monitored as above, with maximal rates 
achieved under each GPx concentration determined by taking the first derivative of the reaction 
trajectory. Maximal rates relative to the control (no GPx) were plotted against their respective 
concentration of GPx. Statistical significance was determined according to Student’s t-test (un-
paired, two-tailed) using Prism (version 4.0) software. Relative Kps were determined by linear 
	   73	  
regression of the plot of decay of cyclooxygenase activity and use of the Km for 15-HpETE and 
15-HpETE-G with each respective enzyme as previously published (39).  
 
Results 
Oxygenation of 2-AG by mCOX-2, hCOX-2, and oCOX-1 - Figure 4 displays the time 
courses of oxygenation of peroxide-free 2-AG and peroxide-free AA following incubation with 
purified recombinant mCOX-2. As reported earlier, the rate and extent of oxygenation were 
approximately 50% lower for 2-AG than AA (Figure 4A)(174). Similar results were obtained in 
incubations of peroxide-free 2-AG or peroxide-free AA with purified recombinant hCOX-2 
(Figure 4B). The rate and extent of oxygenation of 2-AG was approximately 30% lower than for 
AA. Previous reports indicate that 2-AG and AA are equivalent substrates for COX-2 (174), but 
the data with peroxide-free substrates indicate a slight difference in efficiency. Consistent with 
prior findings, 2-AG was a poor substrate for oCOX-1 (174) (Figure 4C).  
Glyceryl hydroperoxides as substrates for the peroxidase activities of mPGHS-2, 
hPGHS-2 and oPGHS-1 - To determine if the glyceryl ester affects the reduction efficiency of a 
substrate by the PGHS peroxidase, we determined the steady-state kinetic values for the 
reduction of 15-HpETE and 15-HpETE-G. 15-HpETE is comparable to PGG2 as a peroxidase 
substrate and has been used as a model for PGG2, which is unstable and difficult to prepare in 
highly purified form (28,210). By extension, we used 15-HpETE-G as a surrogate for PGG2-G. 
Both hydroperoxides were prepared and tested as described in “Experimental Procedures”. 
Heme-reconstituted mPGHS-2, hPGHS-2, or oPGHS1 was incubated with increasing 
concentrations of 15-HpETE or 15-HpETE-G and 1mM of the reducing substrate ABTS. Table I 
summarizes the kcat and Km values for the two substrates and these three enzymes. 
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Table I: Steady-state kinetic parameters for PGHS-1- and PGHS-2-mediated oxidation of ABTS 
by 15-HpETE and 15-HpETE-G 
 
 
 
 
 
 
 
 
 
 
 
 
  
15-HpETE Km (µM) kcat (S-1) kcat/Km (S-1. µM-1) 
oPGHS-1 4.9 ±1.3 34.0 ±3.0 6.9 ±2.3  
mPGHS-2 1.0 ±0.2 6.6 ±0.3 6.4 ±1.5 
hPGHS-2 3.0 ±0.5 9.3 ±0.4 3.2 ±0.8  
15-HpETE-G Km (µM) kcat (S-1) kcat/Km (S-1. µM-1) 
oPGHS-1 4.5 ±1.2 49.0 ±4.0 11.0 ±3.3  
mPGHS-2 8.0 ±2.0 15.0 ±1.0 1.9 ±0.5 
hPGHS-2 4.8 ±0.5 16.1 ±0.4 3.4 ±0.8 
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Figure 4. Time courses of the oxygenation of peroxide free AA and 2-AG by mCOX-2 (A) and hCOX-2 (B). Reaction conditions 
are described under “Experimental Procedures”.  Reactions contained purified recombinant mCOX-2 (400 nM)(A), purified 
recombinant hCOX-2 (400 nM)(B) and 50 µM of either peroxide-free AA or peroxide-free 2-AG. 
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The data revealed lower Km values for mPGHS-2 and hPGHS-2 using 15-HpETE than 
15-HpETE-G (Table I). mPGHS-2 and hPGHS2 also demonstrated lower kcat values using 15-
HpETE relative to 15-HpETE-G (Table I). The efficiency of 15-HpETE and 15-HpETE-G as 
peroxidase substrates for hPGHS-2 (kcat/Km), were very similar (Table I).  In contrast, 15-
HpETE-G was significantly less efficient than 15-HpETE as a peroxidase substrate for mPGHS-
2 (Table I). This difference in kcat/Km stemmed solely from the higher Km for 15-HpETE-G, 
despite the fact that its kcat was actually higher than that of 15-HpETE (Table I). oPGHS-1 
demonstrated kcat and Km values that did not differ significantly for either 15-HpETE and 15-
HpETE-G (Table I). Thus, 15-HpETE and 15-HpETE-G are comparable substrates for the 
peroxidase activities of oPGHS-1 and hPGHS-2, suggesting that the presence of the glyceryl 
ester has minimal effect on the efficiency of peroxide reduction for these enzymes.  
To qualitatively compare the ability of PGG2 and PGG2-G to serve as substrates for the 
POX activity of PGHS-2, we incubated hPGHS-2 with AA or 2-AG for 30 s, extracted the 
incubation mixtures with cold diethyl ether, and analyzed the extracts by LC/MS. Figure 5 
compares the total ion chromatograms and selective ion monitoring profiles of extracts of AA 
and 2-AG incubated with Fe-hPGHS-2 or Mn-hPGHS-2. With Fe-hPGHS-2 and AA, a major 
peak was observed at 6.8 min with m/z 370, corresponding to PGH2 and with Fe-hPGHS-2 and 
2-AG, a major peak was observed at 6.1 min with m/z 444 corresponding to PGH2-G. No peaks 
were observed in either incubation with m/z 386 or m/z 460, corresponding to PGG2 or PGG2-G, 
respectively (Figure 5). Thus, AA and 2-AG are oxygenated to PGG2 and PGG2-G, which are 
efficiently reduced to PGH2 and PGH2-G, respectively. 
Parallel experiments were performed with Mn-PGHS-2, which exhibits POX activity 
levels that are <0.5% of those of Fe-PGHS-2 (Figure 5) (211). Incubations of AA and Mn-
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hPGHS-2 generated LC/MS profiles with a major peak at 7.2 min and m/z 386, which co-eluted 
with a commercial sample of PGG2. A small peak of PGH2 was detected at 6.8 min, as were 
minor peaks at 5.4-5.9 min corresponding to PG’s.  Incubations of 2-AG and Mn-hPGHS-2 
generated LC/MS profiles with a major peak at 6.6 min with an m/z 460 corresponding to PGG2-
G. A small peak of PGH2-G was observed at 6.2 min as was a trace peak at 5.4 min 
corresponding to PG-G’s. These experiments, although qualitative, indicate that PGG2-G and 
PGH2-G are detectable in incubations of 2-AG with hPGHS-2, and that PGG2-G is efficiently 
reduced to PGH2-G by the POX activity of hPGHS-2. The results support the conclusions 
summarized in Table 1 that the glyceryl esters of 15-HPETE and PGG2 are comparable to the 
free acids as substrates for the POX activity of PGHS-2. 
  Activation of the oxygenase activity of oPGHS-1 and mPGHS-2 by 15-HpETE and 15-
HpETE-G - After establishing the steady-state kinetics for the reduction of 15-HpETE and 15-
HpETE-G by the peroxidase active sites of oPGHS-1, hPGHS-2, and mPGHS-2 (Table I) and 
qualitatively comparing the reduction of PGG2 and PGG2-G by hPGHS-2 (Figure 5); we 
evaluated the ability of 15-HpETE and 15-HpETE-G to activate oPGHS-1- and mPGHS-2-
mediated oxygenation of AA in the presence of NaCN, as described in “Experimental 
Procedures”. The time taken to achieve maximal rate was plotted against the concentration of 
exogenous peroxide added (Figure 6, A and B). 15-HpETE and 15-HpETE-G demonstrated a 
concentration-dependent diminution in the time taken to achieve maximal rate of turnover of AA 
with both oPGHS-1 (Figure 6A) and mPGHS-2 (Figure 6 B). These results are consistent with 
the peroxidase kinetics for oPGHS-1, where 15-HpETE and 15-HpETE-G did not differ in 
efficiency as peroxidase substrates (Table I). Likewise, there was no statistically significant 
difference in the ability of 15-HpETE and 15-HpETE-G to activate mPGHS-2 despite the 
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difference observed in the steady-state kinetics for reduction of 15-HpETE versus 15-HpETE-G 
(Table I). 
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AA   Fe-hPGHS-2   2-AG 
                          
AA              Mn-hPGHS-2                               2-AG 
 
 
 
Figure 5. Comparison of the reduction of PGG2 and PGG2-G by the peroxidase activity of PGHS-2. The efficiencies of 
reduction of PGG2 and PGG2-G by hPGHS-2 were determined as described in “Experimental Procedures”.  The LC/MS 
chromatograms demonstrate that after 30 seconds, heme-reconstituted hPGHS-2 reduces in situ generated PGG2 and in situ PGG2-G 
completely to PGH2  (m/z 370.00, RT 6.84) and PGH2-G (m/z 444.00, RT 6.09) to the same extent, respectively. Use of  Mn-hPGHS-2 
demonstrates that our method was robust enough to detect PGH2/PGG2 and PGH2-G/PGG2-G, with high sensitivity (PGG2 m/z 386.00, 
RT 7.21) and (PGG2-G m/z 460.00, RT 6.62). The instability of the endoperoxides is highlighted by the formation of earlier eluting 
species with hPGHS-2 (PGE2/D2  m/z 370.00, RT 5.31/5.49 and PGE2-G /D2-G m/z 444.00 RT 4.70/4.88) from PGH2 and PGH2-
G respectively.  
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Figure 6. Determination of the activation of oxygenase activity in mPGHS-2 (A) and 
oPGHS-1 (B) by 15-HpETE and 15-HpETE-G. (A) A lag was induced in the turnover of 
AA by incubating either oPGHS-1 (60 nM) or (B) mPGHS-2 (120 nM) in standard assay 
buffer containing 250 mM NaCN. Lag time was defined as the time to maximal rate of 
oxygen consumption. Lag time was plotted against the final concentration of either 15-
HpETE () or 15-HpETE-G () in the cuvette. The lag time in the absence of 250 mM 
NaCN and exogenous peroxide () was also plotted. The data are from triplicate 
determinations and are reported as mean ± S.E. 
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Reduction of 15-HpETE and 15-HpETE-G by GPx - We determined the ability of 
GPx to reduce 15-HpETE and 15-HpETE-G as described under “Experimental Procedures”. 
While 15-HpETE  qualitatively appears to be a better substrate for GPx as judged by the 
extent of GSH oxidation (Figure 7), kinetic parameters could not be determined because of 
the limit of the solubility of the substrates under the conditions used. In fact the critical 
micelle concentration for 15-HpETE-G is approximately 70 µM (data not shown). 
 
 
Figure 7. Determination of steady-state kinetic parameters for the reduction of 15-
HpETE and 15-HpETE-G by purified bovine erythrocyte GPx. The ability of GPx to 
reduce 15-HpETE and 15-HpETE-G was determined using the spectrophotometric assay 
described under “Experimental Procedures”. The initial maximal rates of reaction were 
obtained in duplicate over a range of substrate concentrations (78 nM to 50 µM). Data shown 
are from duplicate determinations, with the plots of mean ± S.E generated as described in 
“Experimental Procedures”. While we were unable to obtain steady state kinetic parameters 
owing to the low solubility of 15-HpETE-G, here, we qualitatively demonstrate that 15-
HpETE is a better substrate than 15-HpETE-G.  
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GPx-mediated suppression of the oxygenation of AA and 2-AG by mPGHS-2 and 
hPGHS-2- When hPGHS-2 or mPGHS-2 was incubated with increasing concentrations of 
GSH-Px in the presence of 1 mM GSH, the relative reduction in the rate of oxygenation of 2-
AG was significantly greater than the relative reduction in rate of oxygenation of AA (Figure 
8, A and B). Furthermore, the decrease in oxygenase activity was dependent on the 
concentration of GPx incubated with either hPGHS-2 or mPGHS-2 (Figure 8, A and B). 
These experiments demonstrate that the oxygenation of 2-AG, relative to AA, demonstrates 
greater sensitivity to suppression by GPx. Kulmacz and Lands demonstrated that the 
concentration of peroxide needed to activate the oxygenase activity of PGHS-1 was two 
orders of magnitude lower than the Km of the peroxidase active site of PGHS-1 (39). Using 
the GPx-GSH system to scavenge peroxides from the peroxidase and cyclooxygenase 
reactions of PGHS-1, they determined that the peroxidase activity is 13-fold more sensitive 
to suppression under these conditions, than the cylooxygenase activity (39). From a linear fit 
of the plot of the decay of the cyclooxygenase activity due to suppression by GPx-GSH, they 
were able to calculate the concentration of peroxide required to activate the oxygenase for 
that particular substrate. This value was coined Kp, and incorporates the Km of the peroxide 
intermediate from the substrate’s oxygenation as follows: [KmROOH/ sensitivity factor (POX 
vs. COX)= 13]* dY/dX decay of oxygenase activity under GSH-Px suppression. Km ROOH 
represents the Km of either 15-HpETE or 15-HpETE-G with either mPGHS-2 or hPGHS-2. 
 Here we have determined the relative Kps for AA and 2-AG oxygenation with 
PGHS-2, from the data in Figure 7; these demonstrate that 2-AG requires greater than 3-fold 
and 40-fold more peroxide for the activation of its oxygenation by hPGHS-2 and mPGHS-2 
respectively, relative to AA (Table II). 
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Figure 8. Determination of the ability of the GPx-GSH system to suppress the turnover 
of AA and 2-AG by hPGHS-2 (A) and mPGHS-2 (B).  (A) hPGHS-2 (400 nM)  or  (B) 
mPGHS-2 (400 nM) was incubated with increasing concentrations of GPx (0-160 U) in 
standard assay buffer, and AA () or 2-AG () was added to 50 µM as described in 
“Experimental Procedures”. The maximal rate of oxygen consumption relative to the control 
(no GPx) was plotted against the concentration of GPx. Data are from triplicate 
determinations. Asterisks indicate statistically significant differences in the relative rate of 
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oxygen consumption between AA and 2-AG (Student’s t-test, un-paired, two-tailed-  * 
p<0.05, ** p<0.001, ***p<0.0001) 
 
 
Table II. Cyclooxygenase activation parameters for PGHS-2 with AA and 2-AG 
 AA Kp (µM) 2-AG Kp (µM) Relative Kp (Kp 2-AG/ Kp AA) 
mPGHS-2 0.08 ±0.03 3.1 ±1.5 39 
hPGHS-2 0.2 ±0.1 0.8±0.2 4 
 
The disparity in the relative Kps of 2-AG with mPGHS-2 versus hPGHS-2 are 
somewhat in line with published kcat/Km values for 2-AG with both enzymes. mPGHS-2 
oxygenates 2-AG with half the efficiency of hPGHS-2 (174). Furthermore, the decay in 
oxygenase activity with 2-AG for mPGHS-2 under suppression by GPx-GSH occurs faster, 
relative to hPGHS-2 (Figure 8); at 40 U GPx, the per cent cyclooxygenase activity of 
mPGHS-2 with 2-AG is ~3-fold lower than hPGHS-2 with 2-AG at 40 U GPx. This 
accelerated decay, coupled with an increased Km for glyceryl peroxides with mPGHS-2 
factor into yielding a calculated Kp higher than anticipated, and much higher than that 
obtained for hPGHS-2 with 2-AG. 
Oxygenation of 2-AG by purified recombinant H388Y mPGHS-2 - Having established 
that the oxygenation of 2-AG appears more sensitive to peroxide tone than the oxygenation 
of AA, we investigated 2-AG oxygenation by an mPGHS-2 mutant (H388Y) that has greatly 
diminished peroxidase activity (34). Figure 9 displays the oxygenation of AA and 2-AG by 
purified recombinant wild-type mPGHS-2 and purified recombinant H388Y mPGHS-2.  
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Figure 9. Oxygenation of AA and 2-AG by H388Y mPGHS-2. Wild-type mPGHS2 (400 
nM) was incubated with 50 µM of either AA (—) or 2-AG (- - -), in standard assay buffer, 
as described in “Experimental Procedures”. For comparison, H388Y mPGHS2 (400 nM) was 
incubated with 50 µM of either AA (—) or 2-AG (- - -), in standard assay buffer as 
described in “Experimental Procedures”. Traces are representative of triplicate 
determinations. 
 
The turnover of AA by H338Y mPGHS-2 displays a characteristic lag in its initial 
trajectory relative to that of the wild-type mPGHS-2 (Figure 9).  This lag is effected by 
H388Y mPGH2’s diminished peroxidase activity and subsequent lack of activation of 
oxygenase activity (34). Despite the lag, the extent of oxygenation of AA by H388Y 
mPGHS-2 is the same as that by wild-type mPGHS-2. Interestingly, the turnover of 2-AG by 
H388Y is severely diminished relative to the turnover of 2-AG by wild-type mPGHS-2 
(Figure 9), lacking the distinguishable lag and accelerative phases in its trajectory. This 
result, along with the finding that 2-AG turnover was more sensitive to GPx suppression, 
indicated that 2-AG oxygenation is more sensitive to peroxide activation than AA 
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oxygenation. These results are supported by LC/MS experiments that qualitatively compared 
the levels of PGG2-G to the levels of PGG2 in reactions mixtures of H388Y mPGHS-2 with 
2-AG and AA, respectively, quenched after identical time points (Figure 10). In incubations 
of AA and H388Y, a peak at 7.2 min with m/z 386 corresponding to PGG2 was seen to 
increase with time over the entire 120 sec incubation period. In contrast, in incubations of 2-
AG with the enzyme, the peak at 6.6 min with m/z 460, which corresponds to PGG2-G, was 
present in very low abundance and scarcely increased with time (Figure 10). This indicates 
that PGG2-G levels never approach those of PGG2, so levels necessary to initiate the 
accelerative phase of the cyclooxygenase reaction are not attained. This leads to the 
prolonged lag for 2-AG observed with H388Y mPGHS-2 (Figure 9). 
Stimulation of 2-AG oxygenation by purified recombinant H388Y mPGHS-2 via 15-
HpETE and 15-HpETE-G - In light of the discovery that the turnover of 2-AG was severely 
impaired in H388Y mPGHS-2 and that PGG2-G levels remain extremely low relative to 
PGG2 over the course of 2-AG oxygenation, we incubated H388Y mPGHS-2 with increasing 
concentrations of either 15-HpETE or 15-HpETE-G. Figure 11A demonstrates that 
incubation with either 32 µM 15-HpETE or 32 µM 15-HpETE-G, led to the recovery of 
levels of 2-AG oxygenation equal to those observed with wild-type enzyme. The recovery of 
2-AG oxygenation by H388Y mPGHS-2 was dependent on the concentration of 15-HpETE 
and 15-HpETE-G, with both demonstrating comparable capacity to overcome the lack of 2-
AG turnover (Figure 11B). These data provide further validation that 15-HpETE and 15-
HpETE-G are equivalent activators of oxygenase activity. 
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AA                             30 seconds                          2-AG 
 
 
AA                             60 seconds                          2-AG 
 
AA                             120 seconds                          2-AG 
 
 
Figure 10. Comparison of the levels of PGG2 and PGG2-G over the course of AA and 2-
AG oxygenation by H388Y mPGHS-2. The levels of PGG2 and PGG2-G produced by the 
oxygenation of AA and 2-AG over the course of oxygenation by H388Y mPGHS-2 were 
determined as described in “Experimental Procudures”.  The LC/MS chromatograms 
demonstrate that after 30 seconds robust levels of PGG2 (m/z 386.00, RT 7.21 ) are readily 
detectable, while PGG2-G (m/z 460.00, RT 6.61) is barely detectable. Robust levels of PGG2 
are detectable at 60 and 120 seconds while PGG2-G remains barely detectable at 60 and 120 
seconds. These data indicate that PGG2-G levels from 2-AG oxygenation by H388Y 
mPGHS-2 never approach those of PGG2 with AA and H388Y mPGHS-2.  
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Figure 11.	  Stimulation of oxygenation of 2-AG by H388Y mPGHS-2 via 15-HpETE and 
15-HpETE-G. Wild-type mPGHS2 (400 nM) was incubated with 50 µM of 2-AG (—), in 
standard assay buffer, as described in “Experimental Procedures”. (A) For comparison, 
H388Y mPGHS2 was incubated with 50 µM 2-AG alone (---), or with either 32 µM 15-
HpETE (—) or 32 µM 15-HpETE-G (---) in standard assay buffer as described in 
“Experimental Procedures”. (B) A plot of the rate of His338Tyr mPGHS-2-mediated 2-AG 
turnover, relative to that of wild-type mPGHS-2, was generated over a range of 
concentrations (4 µM- 32 µM) of either 15-HpETE () or 15-HpETE-G (). Data are from 
triplicate determinations. 
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Discussion 
The present study compared the ability of hydroperoxide derivatives of AA and 2-AG 
to serve as substrates for the peroxidase activities of PGHS-1 and PGHS-2 and as activators 
of the cyclooxygenase activities of both enzymes. The results clearly show that the 15-
hydroperoxy derivatives of both molecules are similar in their efficiencies as substrates for 
the PGHS-1 and PGHS-2 peroxidases, and that they activate the cyclooxygenase activities of 
the two enzymes equivalently with AA as the substrate (Table I, Figure 6).  The kcat/Kms for 
oxidation of ABTS by the peroxidase activity of PGHS-1 and PGHS-2 are similar for 15-
HpETE and 15-HpETE-G although there are some small differences (Table I). oPGHS-1 
exhibits a kcat/Km for 15-HpETE-G that is approximately 2-fold higher than for 15-HpETE, 
whereas mPGHS-2 exhibits a kcat/Km for 15-HpETE that is approximately 3-fold higher than 
for 15-HpETE-G. The ability of 15-HPETE-G to serve as a peroxidase substrate and to 
activate the cyclooxygenase activity of oCOX-1 also suggests that the reduced ability of 2-
AG to serve as a substrate for COX-1 (~20-fold) (Figure 4) (174) is not due to an inability of 
hydroperoxides derived from 2-AG (e.g., 15-HpETE-G or PGG2-G) to support peroxidase-
dependent activation. 
Although hydroperoxy derivatives of 2-AG and AA are equivalent in their ability to 
activate PGHS-1 and PGHS-2, we discovered significant differences between 2-AG and AA 
in their sensitivity to oxidation by PGHS-2 which were exhibited under conditions of limiting 
peroxidase-dependent activation. This was unanticipated because 2-AG and AA have similar 
kcat/Kms for oxidation by human or mouse PGHS-2 (174). However, reduction of peroxidase-
dependent cyclooxygenase activation by hydroperoxide scavenging with GSH and GPx or 
utilization of an mPGHS-2 mutant (H388Y) with significantly reduced peroxidase activity, 
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disproportionately affects 2-AG oxidation compared to AA. This is especially dramatic in 
experiments with the H388Y mutant (Figure 9). As reported previously, oxidation of AA by 
this mutant occurs with a pronounced lag phase but eventually an accelerative phase of 
oxidation occurs and the extent of oxidation equals that observed with AA oxidation by wild-
type PGHS-2 (34). In contrast, the lag phase for oxidation of 2-AG by H388Y is so 
pronounced that an accelerative phase of oxidation is not observed, and the enzyme never 
attains a robust rate of 2-AG oxidation (Figure 9).  
  The inability of H388Y to oxidize 2-AG, which is due to a rate of hydroperoxide 
generation from 2-AG insufficient to rapidly activate other inactive PGHS-2 molecules 
(Figure 9), is overcome by the addition of hydroperoxide (Figure 10). Thus, despite the 
similarity of the kcat/Kms of AA and 2-AG, there are differences in their oxidation that are 
only unmasked under conditions of peroxidase deficiency.  The concentration of peroxide 
required for activation of cyclooxygenase activity, Kp, is a significantly lower concentration 
of peroxide than the concentration of peroxide required for half-maximal activity of the 
peroxidase active site (Km), and can be measured under conditions of peroxide depletion by 
GSH and GPx as previously reported (39). We were able to determine the relative Kps of AA 
and 2-AG from our experiments with both hPGHS-2 and mPGHS-2 with GPx, finding that 2-
AG’s Kps differ by 4-fold and ~40-fold, respectively, relative to those of AA (Table II). This 
inherent difference in the requirement for sustained activation of oxygenation with 2-AG 
relative to AA, explains why 2-AG oxygenation demonstrates sensitivity to decreased 
peroxide tone. The 10-fold difference in the Kps of 2-AG with mPGHS-2 and hPGHS-2 are 
somewhat in line with the kcat/Km of 2-AG with both enzymes. hPGHS-2 oxygenates 2-AG 
twice as efficiently as mPGHS-2 (174). Furthermore the decay of 2-AG oxygenase activity 
under suppression by GPx-GSH is 3-fold faster than for mPGHS-2 than for hPGHS-2 (Figure 
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7). Also, the Km for 15-HpETE-G is 8-fold higher than for 15-HpETE, which when factored 
into the calculation of the Kp, leads to a higher than anticipated Kp for 2-AG with mPGHS-2. 
The increased sensitivity of 2-AG relative to AA to reduced peroxide tone is reminiscent of 
the behavior of EPA with PGHS-1. EPA is a poor substrate for oxygenation by PGHS-1 but 
its oxidation is stimulated by exogenous peroxide (212). Examination of the crystal structure 
of EPA with PGHS-1 demonstrates a shift in the conformation of Tyr-385 from its critical 
position near the 13-pro-(S)-hydrogen, leading to poor initiation of EPA oxygenation relative 
to AA (213). Interestingly, EPA is also oxygenated poorly by H388Y mCOX-2 
(Supplemental Figure 1).  Oxygenation can be stimulated by exogenous peroxide but cannot 
reach wild-type mCOX-2 levels of EPA oxygenation (Supplemental Figure 2). Furthermore, 
EPA demonstrates a Kp that is 20-fold greater than that for AA (Supplemental Figure 3 and 
Supplemental Table I), indicating that altered positioning of Tyr-385 near the 13-pro-S-
hydrogen can impact the Kp of a substrate.   Although our laboratory has proposed a model 
for the binding of 2-AG in the PGHS-2 active site that is similar to the conformation of AA 
in the PGHS-1-AA crystal structure (214), this structure has not been confirmed by 
crystallography.  
Taken together, these findings indicate that the oxygenation of 2-AG by PGHS-2 is 
more sensitive to peroxide tone than is the oxygenation of AA.  We propose that this 
phenomenon may be exploited pharmacologically, to prevent the oxygenation of 2-AG by 
PGHS-2.  Recent studies in pain models indicate that increases in endocannabinoid tone lead 
to analgesia (193), so it would be interesting to see whether pharmacological agents that can 
selective block 2-AG oxygenation by PGHS-2, can effect analgesia. The development of 
these agents will be discussed in Chapter IV. 
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Supplementary Material 
 
  
Supplemental Figure 1. Oxygenation of AA and EPA by H388Y mCOX-2. 400 nM of wt 
mCOX2 was incubated with 50 µM of either AA (—) or EPA(- - -), in standard assay 
buffer, as described in “Experimental Procedures”. For comparison, H388Y mCOX2 was 
incubated with 50 µM of either AA (—) or EPA (- - -), in standard assay buffer as described 
in “Experimental Procedures”. Traces are representative of triplicate determinations. 
 
 
  
Supplemental Figure 2. Stimulation of oxygenation of EPA by H388Y mCOX-2 via 15-
HpETE. 400 nM of H388Y mCOX2 was incubated with 50 µM of EPA (—), in standard 
assay buffer, as described in “Experimental Procedures” with increasing concentrations of 
15-HpETE. A plot of the rate of His338Tyr mCOX-2-mediated EPA turnover, relative to that 
!"#$%&'()*'+,-
. /.. &.. 0..
/1.
/2.
/3.
&..
&&.
!"#$%&'()&*+,
-.//0!"#$%&'()&*+,
!"#$%&'()&,,
-.//0!"#$%&'()&,,
45!6'789
:#
&;
'!
<
!"#$%&'&()*+,-./*01(*-234502(46(&78(9:($;<<=(,>?@#A
B !B AB ;B CB
B
AB
CB
DB
<B
!BB
EF??$G!H
I
J
*(,
>
?
@#
A(
(5
0.
4K
+*:
	   96	  
of wild-type mCOX-2, was generated over a range of concentrations (1 µM- 32 µM) of 15-
HpETE. Data are from triplicate determinations. 
 
 
 
 
 
Supplemental Figure 3. Determination of the ability of the GSH-Px-GSH system to 
suppress the turnover of EPA by mCOX-2  mCOX-2 (400 nM) was incubated with 
increasing concentrations of GSH-Px (0-20 U) in standard assay buffer, and AA () or EPA 
() was added to 50 µM as described in “Experimental Procedures”. The maximal rate of 
oxygen consumption relative to the control (no GSH-Px) is plotted against the concentration 
of GSH-Px. Data are from triplicate determinations.  
 
 
Supplemental Table I. Cyclooxygenase activation parameters for mCOX-2 with AA and 
EPA 
 
 AA Kp (µM) EPA Kp (µM) Relative Kp (Kp EPA/ Kp AA) 
mCOX-2 0.08 ±0.03 1.6 ±0.6 20 
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CHAPTER III 
 
 
DETERMINANTION OF THE EX VIVO ROLE OF THE GPX SYSTEM IN THE  PGHS-2-
MEDIATED OXYGENATION OF THE ENDOCANNABINOID 2-AG 
 
Introduction 
Prostaglandin H Synthase-2 (PGHS-2) has been shown to oxygenate the 
endocannabinoid 2- arachidonoyl glycerol (2-AG) in vivo and ex vivo, leading to the 
formation of prostaglandin glyceryl esters (PG-Gs) (Figure 1)(174-176,179). The 
oxygenation of 2-AG leads to a termination of analgesic endocannabinoid signaling, which 
has been proposed to lead to pain (179,193).  The actions of PG-Gs are an area of intense 
investigation. PGE2-G has been shown to stimulate Ca2+ mobilization in RAW264.7 
macrophages via inositol tris-phosphate (IP3) and to induce translocation and activation of 
protein kinase C (PKC) in a concentration-dependent manner independent of its hydrolysis to 
PGE2 (178).  Both PGE2-G and PGF2α-G also stimulate Ca
2+ mobilization in H1819 non-
small cell lung carcinoma cells with EC50s of  ~ 0.6 pM and ~ 0.5 pM respectively (215). 
Both PGF2α-G and PGE2-G has been shown to bind at unique, yet to be identified G-protein-
coupled receptors (GPCR) (178,179,215). 
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Figure 1. Oxidative Metabolism of 2-AG by PGHS-2- 2-AG is efficiently oxygenated by PGHS-2 to PGH2-G and PGH2-G is 
efficiently isomerized to prostaglandins analogs to those derived from AA, with the exception of thromboxane synthase, for which 
PGH2-G is a poor substrate (175). 
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The possibility that PGHS-2-dependent metabolism of analgesic 2-AG may play a 
role in the mediation of pain has become an attractive hypothesis. Indeed, PGE2-G has 
been shown to cause an increase in the gain in the pain system leading to an exaggerated 
pain response (hyperalgesia) and pain in response to non-pain evoking stimuli (allodynia) 
(179).  While the steady state kinetic parameters of the oxygenation of 2-AG and AA by 
PGHS-2 in vitro are virtually identical (174), examination of the formation of PG-Gs ex 
vivo demonstrates that they are detected at levels 1000-fold lower than those of AA 
derived prostaglandins (PGs), upon stimulation of murine resident peritoneal 
macrophages with an inflammatory stimulus (176).  While the levels of 2-AG released 
upon stimulation by inflammatory stimuli are only 10-fold lower than the levels of AA, 
there is incongruity between the levels of 2-AG and PG-Gs realized (176). This is further 
confounded by the fact that 2-AG is rapidly hydrolyzed by monoacylglycerol lipase 
(MAGL) to AA, and PG-Gs are also subject to hydrolysis to PGs by an active, unique, 
and yet to be identified serine hydrolase (177).  
Despite all of these factors, it is now apparent that the oxygenation of 2-AG is 
exquisitely sensitive to peroxide-mediated activation of PGHS-2 (Chapter II).  Peroxide 
tone in the cell has been shown to be critical for PGHS-2 activation and PG formation 
(140,141). Peroxide tone is modulated by the glutathione peroxidase-glutathione system 
(GPx-GSH) which reduced fatty acid hydroperoxides to alcohols (216). There are four 
known mammalian GPxs: GPx1-4. The brunt of oxidant homeostasis is borne by GPx1, 
however, GPx4 is the only isoform that can reduce phospholipid bound hydroperoxides 
(216). In fact, knock-out of GPx4 in mouse embryonic fibroblasts has been shown to 
cause embryonic lethality by overt increases in lipid peroxidation (110). Interestingly, 
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over-expression of GPx4 has been shown to mute PGD2 synthesis in activated mast cells 
(141), while siRNA knock-down of GPx4 has been shown to double the formation of 
PGs in human epidermoid carcinoma (140). This has led us to hypothesize that increasing 
peroxide tone by impairment of the endogenous peroxide detoxification mechanism could 
lead to increased 2-AG oxygenation by PGHS-2. 
I report that stable silencing of GPx4 using shRNA in murine NIH/3T3 fibroblasts 
leads to an increase in lipid peroxidation and oxidant stress relative to GPx1-silenced 
cells and scrambled shRNA controls. Furthermore, silencing of GPx4 in these cells leads 
to a doubling of PG-G production following stimulation. These observations extend my 
in vitro findings discussed in Chapter II, and demonstrate that PG-G formation in the cell 
is sensitive to peroxide tone. Also, the detection of PG-Gs in a widely used mammalian 
cell line gives credence to the relevance of PGHS-2-mediated, 2-AG oxygenation. 
 
Experimental Procedures 
RNA interference - Low-passage murine NIH/3T3 fibroblasts were cultured in 
DMEM (10% heat-inactivated FBS) and plated in 100 mm dishes at 75% confluence. 
Cells were cultured at 37°C and 5% CO2 (v/v). shRNA plasmids (scrambled-negative 
control, GFP positive control, Gpx1, and Gpx4) were obtained from Santa Cruz (Santa 
Cruz, CA). Transfection was carried out following the manufacturer’s instructions, with 
selection of successfully transfected cells achieved by including 10 µg/mL puromycin 
(Sigma-Aldrich) in the growth medium. Selection was carried out for two weeks. 
  Immunoblotting for GPx protein expression - For the immunoblotting of GPx, 
monolayers of each shRNA-treated NIH/3T3 cell line from 35 mm dishes were lysed in 
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200 µl M-PER lysis buffer (Thermo) containing a cocktail of mammalian protease 
inhibitors (Sigma). Cell lysates were mixed by vortexing and placed on ice for 30 min. 
Cellular debris was then removed by centrifugation for 10 min at 16,000 g.  Samples 
were stored at -80 °C until analyses could be completed. Equal quantities of protein (~ 20 
µg) were resolved by gradient (2-12%) SDS-Polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto a polyvinylidene difluoride membrane (Immobilon-P, 
Millipore). Membranes were blocked (20 mM Tris, pH 7.6, 140 mM NaCl, 0.05% Tween 
20, 5% nonfat dry milk) prior to incubation with antibodies. The primary antibodies, 
αGPx1 and αGPx4 (R&D systems), were used at 1:1000 and the secondary antibodies at 
1:5000 (R&D systems) dilution. Luminol-based detection was performed using 
SuperSignal West Pico reagents (Thermo Scientific). 
Stimulation of PG and PG-G synthesis in shRNA-treated cell-lines - Murine 
NIH/3T3 fibroblasts were plated at 1,000,000 cells per well, in 6-well dishes in media 
with 10 µg/mL puromycin and allowed to attach overnight. PG and PG-G production  
was stimulated by incubation with 12-O-tetradecanoylphorbol-13-acetate 
(TPA)/ionomycin (0.08 µM/2 µM) for 4 hours.  
Assay for production of PGs, PG-Gs by cultured cells - Media from cell cultures 
were subjected to liquid-liquid extraction as developed by Kingsley et al. (217) with 
some modifications as follows. Briefly, internal standards [(100 pmol of the following: 
PGD2-d4, PGE2-d4, PGF2α-d4, and 6-keto-PGF1α-d4, and 10 pmol of the following: 
PGD2-G-d5, PGE2-G-d5, PGF2α-G -d5, 6-keto-PGF1α-G-d5)] were added to medium (2 
mL). The medium was acidified by the addition of glacial acetic acid to 1% (volume), 
followed by 2 mL of ethanol and 2 mL of hexanes:ethyl acetate (20:80 v:v). Samples 
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were vortexed and centrifuged at 3000 RPM for 20 minutes. The organic layer was 
retrieved and evaporated to dryness under a stream of nitrogen. Samples were 
resuspended in 300 µL of methanol:water (50:50 v:v) and analyzed as previously 
described (217). 
Assay for lipid peroxidation and oxidant stress- Murine NIH/3T3 fibroblasts were 
cultured in Dulbecco’s Modified Eagle Medium (DMEM) with 10% heat-inactivated 
fetal bovine serum (FBS) and plated in 100 mm dishes at 75% confluence. Cells were 
incubated with (2 µM) boron-dipyrromethene (BODIPY) 581/591 C11, (Invitrogen, 
USA) overnight for flow cytometry analysis. BODIPY when oxidized exhibits a shift in 
fluorescence from red to green (110). Cells were washed once with cold-Ca2+- and Mg2+-
free  phosphate-buffered saline (PBS), trypsinized, and resuspended in 10% FBS DMEM.  
Cells were loaded onto a 5-laser BD LSRII flow cytometer, equipped with a 535 nm 
laser. 10,000 cells were analyzed for each sample, with scrambled shRNA-treated 
NIH/3T3 as the baseline for peroxidation. A histrogram of each cell line was generated, 
with a threshold set as P1 for cells exhibiting shifts from red to green fluorescence. 
Analysis for oxidative-stress marker, 8-isoprostane (8-epi PGF2α) was carried out by the 
eicosanoid core (Ginger Milne) as previously published (218). 
 
Results 
RNA interference- shRNA-mediated GPx depletion was determined by immunblot 
for each respective GPx.  Relative to the scrambled control, a knockdown of  ~50% of 
GPx1 and ~75% of GPx4 was achieved (Figure 2).  
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Figure 2. Determination of the levels GPx1 and GPx4 following shRNA-mediated 
silencing  (A) Immunoblot for GPx1 and GPx4 in NIH/3T3 fibroblasts transfected with 
shRNA plasmids to knock-down GPx1 and GPx4 as described in “Experimental 
Procedures”. (B) GPx1 is depleted to ~50% below control shRNA and GPx4 to ~75% 
below control shRNA. Asterisks indicate statistically significant differences in the levels 
of GPx1 and GPx4 in GPx1 and GPx4  shRNA transfected NIH/3T3 fibroblasts, relative 
to a scrambled shRNA control (Student’s t-test, un-paired, two-tailed-   ** p<0.001). 
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Figure 3. Determination of the impact of shRNA-mediated silencing of the GPx 
system on peroxide tone in murine NIH/3T3 fibroblasts. Lipid peroxidation was 
assayed using the membrane-specific dye BODIPY and flow cytometry as described in 
“Experimental Procedures”. (A) Histograms of 10,000 cell counts for each shRNA-
treated cell line. A larger proportion of anti-GPx4 shRNA-treated 3T3 fibroblasts 
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demonstrates a green fluorescence shift from red as BODIPY is oxidized. (B) 
Quantitation of the proportions of cells shifting fluorescence past the pre-set threshold 
(P1) revealed that anti-GPx4 shRNA-treated 3T3 fibroblasts demonstrate a greater than 
3-fold increase in lipid peroxidation over control shRNA- and anti-GPx1 shRNA-treated 
3T3 fibroblasts. 
 
 Determination of the effect of GPx1 and GPx4 knockdown on peroxide tone and 
oxidant stress - Following the determination that adequate depletion of GPx1 and GPx4 
was achieved, we evaluated the levels of lipid peroxidation in each cell line as described 
in “Experimental Procedures”. Flow cytometric determination demonstrates that anti-
GPx4 shRNA-treated fibroblasts demonstrate 3-fold more lipid peroxidation relative to 
scrambled control shRNA-treated fibroblasts. Anti-GPx1 shRNA-treated fibroblasts did 
not differ from control (Figure 3A and B). Interestingly, examination of the histograms 
from the BODIPY assay indicate that the anti-GPx4 shRNA-treated fibroblasts display a 
bi-modal distribution in its population. Part of this population extends past the threshold 
P1, indicating that a significant proportion of these cells are shifting their fluorescence 
away from baseline indicative of increased BODIPY oxidation. Furthermore 
measurement of levels of oxidant-stress biomarker, 8-isoprostane, revealed that anti-
GPx4 shRNA-treated fibroblasts demonstrate statistically significant higher levels of this 
marker, relative to scrambled control shRNA-treated fibroblasts (Figure 3C). 
Determination of the effect of GPx1 and GPx4 knockdown on PG and PG-G 
Synthesis - Following the demonstration that depletion of GPx4 could lead to increased 
lipid peroxidation, we determined the effect of increased peroxide tone on PG and PG-G 
synthesis. Following agonist treatment, control, anti-GPx1 and anti-GPx4 shRNA-treated 
cells all demonstrated similar levels of PG synthesis (Figure 4). Interestingly, the two 
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major species of PG-G generated by fibroblasts, PGE2-G and PGF2α-G, were elevated 2- 
and 4-fold, respectively, in anti-GPx4 shRNA-treated fibroblasts, relative to control. 
Anti-GPx1 shRNA-treated cells did not differ from control. 
 
 
Figure 4. Determination of the impact of shRNA-mediated silencing of the GPx 
system on PG and PG-G production by murine NIH/3T3 fibroblasts.  Anti-GPx4 
shRNA-treated 3T3 fibroblasts demonstrate 2-4 fold increases in PG-G production over 
control shRNA- and anti-GPx1 shRNA-treated 3T3 fibroblasts. PG production is not 
significantly different across the three cell-lines. 
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Discussion 
This study extends previous findings from resident peritoneal macrophages and 
RAW264.7 macrophages, where treatment with inflammatory agonists and/or Ca2+ 
ionophores leads to the formation of PG-Gs from 2-AG.  Here we demonstrate that a 
commonly used fibroblast cell line, murine NIH/3T3 fibroblasts, also generate 
appreciable amounts of PG-Gs following an inflammatory stimulus following treatment 
with a Ca2+ ionophore. Furthermore, this study is an extension of the work discussed in 
Chapter II, where we demonstrated that PGHS-2-mediated 2-AG oxygenation was 
sensitive to peroxide tone. Here we establish a role for the phospholipid hydroperoxide 
glutathione peroxidase (GPx4) in the modulation of peroxide tone in murine NIH/3T3 
fibroblasts. Specifically, shRNA-mediated depletion  (~75%) of GPx4 leads to a 3-fold 
increase in lipid peroxidation (Figure 2) and is consistent with literature reports of this 
enzyme’s role in redox homeostasis at the lipid bilayer (131-134). Interestingly, while 
shRNA-mediated depletion of GPx1 (~50%) was statistically different from control 
shRNA fibroblasts (Figure 2), there was no effect on lipid peroxidation noted for this 
level of knock-down (Figure 3). It is possible that the levels of depletion achieved under 
these conditions were not sufficient to observe any effects. GPx-1 knock-out mice do not 
have an overt phenotype, developing normally and only succumbing to exceedingly high 
levels of oxidant stress (113,114). Therefore, with the depletion demonstrated here 
(~50%), it is not surprising that there is no overt phenotype. However, these data do not 
exclude the possibility that further depletion of GPx1 may lead to similar effects as 
observed with Gpx4 depletion.  
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 As discussed before, peroxide tone is more critical for the initiation of 2-AG 
oxygenation in vitro (Chapter II) than for the initiation of AA oxygenation. Here, we 
demonstrate that increasing peroxide tone in NIH/3T3 fibroblasts leads to 2- and 4-fold 
increases in the oxygenation of 2-AG to PGE2-G and PGF2α-G, respectively (Figure 4).  
Interestingly, PGE2 and PGF2α production did not change significantly under these 
conditions, and it appears that PG-Gs are produced at levels 100-fold lower than PGs, 
making changes in PG-G production easier to discern (Figure 4). The fact that AA 
derived PGs do not increase under these conditions may indicate that AA and 2-AG are 
oxygenated in separate cellular compartments, since increased peroxide tone would 
stimulate AA oxygenation as well as 2-AG oxygenation by PGHS.  
These results are the first indication that increased peroxide tone leads to 
increased 2-AG oxygenation by PGHS-2 and are congruent with previous reports on the 
role of peroxide tone in AA oxygenation by PGHS (140,141). Inflammatory states are 
associated with increases in redox stress and the relevance of 2-AG oxygenation by 
PGHS could play a role under these conditions, leading to increased conversion of the 
analgesic 2-AG, to a pro-inflammatory and hyperalgesic PGE2-G.  These findings 
provide further credence to the PGHS-2/2-AG axis in the mediation of pain and 
demonstrate that under increased cellular oxidant stress, PGHS-2-mediated oxygenation 
of 2-AG may be augmented. 
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CHAPTER IV 
 
 
TARGETTING THE POX ACTIVE SITE OF PGHS-2 FOR THE SELECTIVE 
INHIBITION OF PGHS-2 MEDIATED OXYGENATION OF THE 
ENDOCANNABINOID 2-AG 
 
Introduction 
Prostaglandin H Synthase-2 (PGHS-2) has been shown to oxygenate the 
endocannabinoid 2- arachidonoyl glycerol (2-AG) in vivo and ex vivo, leading to the 
formation of prostaglandin glyceryl esters (PG-Gs) (174-176,179). The relevance of these 
findings has been questioned since PG-Gs are detected at low levels relative to AA-
derived prostaglandins (PGs) (176,179). This is partly due to the hydrolysis of 2-AG to 
AA by an active and specific serine hydrolase, monoacyl glycerol lipase (MAGL) (144), 
reducing the amounts of 2-AG available for oxygenation by PGHS-2 (176). Furthermore, 
PG-Gs are rapidly hydrolyzed in vivo, by an unidentified serine hydrolase (177). 
Effectively, these data indicate that a proportion of PGs detected in vivo may be 2-AG-
derived, either from hydrolysis of 2-AG or PG-Gs. Indeed, co-incubation of 2-AG with 
murine peritoneal macrophages effectively leads to both increased PG and PG-G 
generation (176).  It has therefore been difficult to demonstrate specifically the 
contribution of 2-AG metabolism by PGHS-2, and its relevance in diminution of 
analgesic endocannabinoid tone.   
Non-steroidal anti-inflammatory drugs (NSAIDs), are inhibitors of fatty acyl 
substrate (FAH) oxygenation by PGHS and do so by competing with the substrate for 
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binding in the oxygenase active site of PGHS. Functional PGHS is made up of two 
homodimers, and binding of substrate or FAH in one of these monomers is thought to 
cause a conformational change in the other, rendering it incapable of oxygenation of 
FAH.  In fact titrations of three different NSAIDS, indomethacin, flurbiprofen and 
meclofenamic acid, against functional PGHS homodimers demonstrated that it took one 
molecule of NSAID per homodimer to effect inhibition of AA oxygenation (219). This 
phenomenon has been dubbed half-sites reactivity. Recent work has demonstrated that 
weak inhibitors of AA oxygenation by PGHS-2 are about 100-fold more potent as 
inhibitors of 2-AG oxygenation (220). This phenomenon has been dubbed substrate-
selective inhibition and has been proposed to be related to the half-sites reactivity of 
PGHS. Prusakiewicz et al. proposed that when weak reversible NSAIDs bind one 
monomer, they can effect a conformational change that reduced the affinity of the other 
monomer for 2-AG, which leads to a dimunition of 2-AG oxygenation (220). The 
inhibition of AA oxygenation by PGHS-2, however, requires the binding of these weak 
NSAIDs in both monomers of the PGHS homodimer (220). This finding could explain 
the analgesic effects of weak NSAIDs, which are not fully explained by the inhibition of 
AA oxygenation (221). 
To further this concept of selectively inhibiting the oxygenation of 2-AG over that 
of AA, we targeted the peroxidase active site of PGHS-2. The findings reported in the 
preceding two chapters (Chapter II and Chapter III) indicate that the oxygenation of 2-
AG by PGHS-2 is sensitive to peroxide tone.  Increasing concentrations of GPx lead to a 
selective suppression of 2-AG oxygenation by PGHS-2 relative to AA. Furthermore, 
mutation of the heme-binding residue in the POX active site (His388Tyr), leads to ~ 300-
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fold reduction in peroxidase activity (34). H388Y PGHS-2 retains its ability to oxygenate 
AA, but does not appreciably oxygenate 2-AG (Chapter II).  This defect was restored to 
wild-type levels with exogenous peroxide in a concentration-dependent manner (Chapter 
II).  The sum of all of these data indicate that competitive inhibition of the peroxidase 
activity of PGHS could lead to reduced peroxide-mediated activation of oxygenase 
activity, selectively inhibiting the oxygenation of 2-AG. 
While a variety of structurally and chemically distinct agents have been 
successfully generated to target the COX active site of PGHS, none has been reported for 
the POX active site to date.  The difficulty in designing specific ligands to target the POX 
active site is a testament to the relative promiscuity of this site for substrates, relative to 
the specific determinants for binding in the COX active site. While the POX active site is 
largely solvent accessible and relatively open to its environment, lipophilic 
hydroperoxides such as 15-hydroperoxyeicosatetraenoic acid (15-HpETE) have been 
shown to be reduced more efficiently than smaller peroxides such as hydrogen peroxide 
(H2O2) (34,209). Peroxynitrite (ONOO-) is perhaps the single exception to this rule as it 
is reduced at a rate that is comparable to those of PGG2 and 15-HpETE (27). 
Chubb et al. have modeled PGG2 (Figure 1A) in the POX active site of ovine 
PGHS-1 and demonstrated that the majority of the interactions of PGG2 with the POX 
active site are hydrophobic (222). Their best conformer aligns the 15-hydroperoxide on 
PGG2 with the Fe3+ in the heme of PGHS-1, forming the sixth heme ligand. This 
alignment, coupled with the aforementioned hydrophobic interactions, forms a productive 
complex revealing how the POX active site binds and reduces PGG2.  To design an agent 
that could putatively fulfill the majority of these interactions, we designed a PGG2 mimic, 
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2-methyl-4,5-dihexylimidazole, putatively fulfilling the hydrophobic interactions and 
possibly forming the sixth heme ligand (Figure 1B). Here we report that this agent is a 
selective inhibitor of 2-AG oxygenation with little to no impact on AA oxygenation over 
the concentrations tested. Furthermore, 2-methyl-4,5-dihexylimidazole is a potent 
selective inhibitor of 2-AG oxygenation in agonist-treated RAW264.7 macrophages, 
effectively preventing the conversion of 2-AG to PG-Gs. This represents the first ligand 
to inhibit the POX active site of PGHS and presents a substrate-selective inhibitor of 2-
AG oxygenation by PGHS-2. 
 
 
 
Figure 1. Structure of PGG2 (A) and 2-methyl-4,5-dihexyl imidazole (B). 2-methyl-
4,5-dihexyl imidazole was designed to mimic the reported binding parameters of PGG2 in 
the POX active site of PGHS(222).  
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Experimental Procedures 
 
Chemistry- 2-Methyl 4,5- dihexylimidazole and its analogs, were generated by 
Andy Liedtke as follows: 
Reaction Scheme: 
 
 
Reagents and Conditions: (i)(223) KMnO4, NaHCO3, MgSO4, acetone, H2O, rt, 4h 
(ii)(224) 1,3-dimethylbenzimidazolium iodide, DBU, dioxane, reflux, 3 h, (iii)(225) NBS, 
CCl4, pyridine, 80-85 ˚C, 1.5 h, (iv) NH4OAc, acetaldehyde, InCl3 x 4 H2O, MeOH, rt, 
16h (v)(226,227) formamide, AcOH, µwave radiation, 180 ˚C, 5 min, (vi)(227) 
aliphatic/aromatic aldehyde, NH4-acetate, AcOH, µwave radiation, 180 ˚C, 5 min. 
 
Enzymes - hPGHS-2 and mPGHS-2 were expressed and purified as described 
(206). oPGHS-1 was purified from ram seminal vesicles (Oxford Biomedical Research, 
Oxford, MI), as previously described (207).  The specific activities of hPGHS-2 and 
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mPGHS-2 were both 62.5 µM AA per µM enzyme; oPGHS-1 was 325 µM AA per µM 
enzyme. H388Y mPGHS-2’s specific activity was 31.3 µM AA per µM enzyme 
PPHP reduction assay for peroxidase activity - Determination of the inhibition of 
the peroxidase active site of PGHS were carried out by monitoring the oxidation of 
ABTS (2,2’-azinobis(3-ethylbenzothiazoline-6-sulfonic acid) with 5-phenyl-4-pentenyl 
hydroperoxide (PPHP) as a peroxidase substrate, as previously published (228). 
LC/MS assay for in vitro COX activity and inhibition - Hematin-reconstituted 
PGHS-2 was incubated with inhibitor (0.25 - 50 µM) for 15 min at 37°C prior to the 
addition of 50 mM substrate (AA or 2-AG). The reaction was quenched after 30 seconds 
with ethyl acetate containing 0.5% acetic acid and deuterated internal standards.  The 
organic layer was extracted and evaporated under nitrogen to near-dryness. The residue 
was resuspended in 50:50 methanol:water, and product formation was monitored using 
LC-MS/MS. Products were separated on a Luna C18(2) column (5.0 cm x 0.2 cm, 3 µm) 
using an isocratic method consisting of 65% 5 mM ammonium acetate, pH 3.5 and 35% 
acetonitrile (v/v) at a flow rate of 0.375 mL/min. The triple-quadrupole mass 
spectrometer was operated in positive ion mode using electrospray ionization and 
selective reaction monitoring (SRM) to detect PGs and PG-Gs.  The following transitions 
were monitored: for PGE2/D2 m/z (M+NH4+), 370317, for PGE2/D2-d4 m/z (M+NH4+) 
374321, for PGE2/D2-G m/z (M+NH4+) 444391 and for PGE2/D2-G-d5 m/z 
(M+NH4+) 449396. Products are quantitated as a ratio of the area of the peak to its 
corresponding internal standard and normalized to a DMSO control. 
Thin Layer Chromatography assay for in vitro COX activity and inhibition- 
Hematin-reconstituted enzyme and inhibitor were pre-incubated for 17 min at room 
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temperature followed by a 3 min incubation at 37 °C prior to addition of 50 µM [1-14C]-
AA for 30 sec at 37 °C. The reactions were then terminated by extraction with diethyl 
ether/methanol/citrate (30:4:1) and analyzed for substrate consumption by thin-layer 
chromatography as previously described (229). All inhibitor concentrations for 50% 
enzyme activity (IC50) were determined by nonlinear regression analysis using Graphpad 
Prism software and are the average of multiple determinations of duplicate analyses. 
Inhibitors were prepared as stock solutions in dimethyl sulfoxide (DMSO), and diluted 
into reaction buffer so that the final DMSO concentration was 2.5%. Reactions were run 
with hematin-reconstituted proteins at final enzyme concentrations adjusted to give 
approximately 30- 35% substrate consumption (mCOX-2 = 154 nM). AA was prepared 
as a stock solution in 0.1 N NaOH. 
LC/MS assay for ex vivo COX activity and inhibition -RAW 264.7 macrophages 
were plated at 3 million cells/dish in 3 ml Dubelcco’s Modified Eagle Medium (DMEM) 
with 10% heat-inactivated fetal bovine serum (HI-FBS). After 4 hours, the medium was 
replaced, and 20 ng/mL mouse GM-CSF was added. Following overnight incubation, the 
medium was replaced with DMEM with no FBS, and the cells were treated with 100 
ng/mL LPS, 20 units/ml IFN γ, and 10 µM 15(S)-HETE. Treatment with DMSO vehicle 
or drug was performed at either 0 or 2 hours, and the medium was collected with 2 
equivalents of ethyl acetate plus 0.1% glacial acetic acid spiked with deuterated internal 
standards. The solution was vortexed for 1 minute and then frozen overnight. The organic 
layer was extracted, evaporated to dryness under a stream of nitrogen gas, and 
reconstituted in 150 µl water:methanol (1:1 v:v). The samples were then analyzed by 
reverse-phase liquid chromatography using an Ascentis C18 (5 cm x 2.1 mm with 3 µm 
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particle size) column and mobile phases of 5 mM ammonium acetate in water, pH of 3.4 
and acetonitrile :water (94:6 v:v). Mass spectral analysis was conducted on a 
Thermofinnigan triple quadrupole mass spectrometer in positive ion mode using SRM. 
The product amounts were calculated by integrating the peak areas of the samples and 
comparing them to the area of the spiked deuterated standard peaks. The product 
identities were confirmed by comparing the retention times and collision-induced 
dissociation spectra to standards. The following transitions were monitored: for PGE2/D2 
m/z (M+NH4+), 370317, for PGE2/D2-d4 m/z (M+NH4+) 374321, for PGE2/D2-G m/z 
(M+NH4+) 444391 and for PGE2/D2-G-d5 m/z (M+NH4+) 449396. The data were 
analyzed using Xcalibur and then graphed and analyzed in GraphPad Prism. 
 
Results 
Assay for 2-methyl 4,5 dihexylimidazole as a Peroxidase Inhibitor - 
Determination of the inhibition of the peroxidase active site of PGHS were carried out by 
monitoring the oxidation of ABTS as the reducing co-substrate with PPHP as a 
peroxidase substrate, as previously published (228). 2-Methyl 4,5 dihexylimidazole 
modest inhibitor of the POX activity of  PGHS-2 (Figure 2), never achieving greater than 
50% inhibition of the reduction of PPHP. 2-Methyl 4,5 dihexyl imidazole did not inhibit 
the peroxidase activity of PGHS-1 (data not shown). 
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Figure 2. Inhibition of the peroxidase active site of PGHS-2.  2-Methyl-4,5-dihexyl 
imidazole was tested against the peroxidase active sites of PGHS-2 in inhibiting the 
reduction of PPHP in a spectrophotometric assay monitoring the oxidation of ABTS as 
the reducing co-substrate as previously published (230). 
 
Assay for 2-methyl-4,5-dihexylimidazole as an inhibitor of AA and 2-AG 
oxygenation – To determine if the inhibition of the peroxidase active site by 2-methyl-
4,5-dihexyl imidazole could inhibit the oxygenation of either AA or 2-AG, we tested it as 
described in “Experimental Procedures”. 2-Methyl-4,5-dihexyl imidazole is a selective 
inhibitor of 2-AG oxygenation, with an IC50 of ~ 8.3 µM, with no impact on AA 
oxygenation (Figure 3). 
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Figure 3. Selective inhibition of PGHS-2 oxygenation of 2-AG by 2-methyl-4,5-
dihexyl imidazole, in vitro. 2-Methyl-4,5-dihexyl imidazole was tested for its ability to 
inhibit the oxygenation of AA and 2-AG by PGHS-2. 2-Methyl-4,5-dihexyl imidazole 
demonstrated an IC50 of 8.3 µM against 2-AG, with no inhibition of AA oxygenation.  
 
Assay for 2-methyl-4,5-dihexylimidazole as competitive COX inhibitor- Since 
weak COX inhibitors have been shown to be potent selective 2-AG inhibitors in vitro 
(220),  we determined the ability of  2-methyl-4,5-dihexylimidazole to bind at the COX 
active site. We determined the IC50 of a weak reversible inhibitor, ibuprofen, alone, or in 
the presence of 25 µM of 2-methyl-4,5-dihexylimidazole. As shown in figure 4, testing of 
ibuprofen in the presence of 2-methyl-4,5-dihexylimidazole slightly potentiates the 
inhibitory actions of ibuprofen, demonstrating a slight leftward shift in the IC50 curve.  
This indicates that under these conditions, 2-methyl-4,5-dihexylimidazole does not 
interact with ibuprofen at the COX active site. Had the IC50 curve had demonstrated a 
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rightward shift, this would been an indication 2-methyl-4,5-dihexylimidazole can actively 
bind at the COX active site and possibly effect inhibition.  
 
 
Figure 4. Determination of the ability of 2-methyl-4,5-dihexyl imidazole to bind at 
the COX active site of PGHS-2- The IC50 of ibuprofen was determined either alone, or 
in the presence of 25 µM 2-methyl-4,5-dihexyl imidazole (Drug). The potency of 
ibuprofen is not affected by the presence of 25 µM 2-methyl-4,5-dihexyl imidazole 
indicating that 2-methyl-4,5-dihexyl imidazole does not effectively bind at the COX 
active site. 
 
Assay for 2-methyl-4,5-dihexylimidazole as an inhibitor of AA and 2-AG 
oxygenation in activated  RAW264.7 macrophages– Following the demonstration that 2-
methyl-4,5-dihexyl imidazole was a selective inhibitor of 2-AG oxygenation in vitro, we 
used RAW264.7 macrophages which have been shown to generate robust amounts of 
PGs and PG-Gs in response to physiologic inflammatory stimulus and Ca2+ ionophore 
(174).  This was carried out as described in “Experimental Procedures”. Interestingly, 2-
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methyl-4,5-dihexyl imidazole inhibited AA oxygenation, with an IC50 of ~ 14 µM and 2-
AG oxygenation with and IC50 ~ 25 nM.  
 
 
 
Figure 5. Selective inhibition of oxygenation of 2-AG by 2-methyl-4,5-dihexyl 
imidazole in activated murine RAW264.7 macrophages. 2-Methyl-4,5-dihexyl 
imidazole was tested for its ability to inhibit the oxygenation of AA and 2-AG in 
RAW264.7 macrophages as described in “Experimental Procedures”. 2-Methyl-4,5-
dihexyl imidazole demonstrated an IC50 of  < 14 nM against 2-AG, and 14 µM against 
AA oxygenation.  
 
Discussion 
The present study reports that a modest peroxidase inhibitor of PGHS has been 
successfully generated, and that it is a selective inhibitor of the oxygenation of 2-AG both 
in vitro and ex vivo. 2-Methyl-4,5-dihexyl imidazole, while a modest inhibitor of the 
peroxidase active site, is a potent inhibitor of 2-AG oxygenation against purified enzyme 
and in RAW264.7 macrophages treated with inflammatory stimuli. These findings are in 
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agreement with previous findings that demonstrate that 2-AG oxygenation is sensitive to 
peroxide depletion in vitro and ex vivo (Chapter II and Chapter III). Here we have further 
confirmation of this finding through the selective attenuation of 2-AG oxygenation by a 
peroxidase active site inhibitor.  While this represents the first peroxidase inhibitor of 
PGHS, a report of a similar compound, 2-methyl imidazole, has been shown to interact 
with the peroxidase active site of a mutant PGHS-2 (231).  2-Methyl imidazole was able 
to restore full peroxidase activity in a peroxidase active site mutant, His193Ala PGHS-2, 
that exhibited ~200-fold diminished POX activity relative to wild-type PGHS-2 (231). 
While the action of 2-methyl-4,5-dihexyl imidazole has the opposite effect on wild-type 
PGHS-2, the fact that these ligands share close structural similarity and interact with the 
peroxidase active site might indicate that imidazole-based compounds could form an 
appropriate scaffold to explore the structure activity of future inhibitors based on 2-
methyl-4,5-dihexyl imidazole.  
The development of a potent substrate-selective inhibitor of 2-AG oxygenation by 
PGHS-2 could be very useful in the determination of the contribution of PGHS-2 in the 
mediation of pain.  While some weak NSAIDs have also been shown to be very potent 
selective inhibitors of PGHS-2-mediated 2-AG oxygenation (220), their use as 
experimental probes is confounded by the fact that many of these same compounds have 
also been shown to inhibit fatty acid amide hydrolase (FAAH) (232). FAAH is the chief 
enzyme that metabolizes the endocannabinoid anandamide (AEA) hydrolyzing it to AA.  
The use of these weak NSAIDs to dissect the exact contribution PGHS-2-mediated 
oxygenation of 2-AG to pain control could be complicated by the preservation of AEA 
levels from FAAH inhibition (232).  
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These results along with those from the preceding chapters indicate that the oft-
ignored peroxidase active site of PGHS is a veritable pharmacological target. Future 
work should be geared toward the generation of analogs of 2-methyl-4,5-dihexyl 
imidazole, which could also be used to probe the molecular determinants of the 
interations of peroxidase active site inhibitors with the POX active site of PGHS. 
Furthermore testing of promising analogs of 2-methyl-4,5-dihexyl imidazole in an ex vivo 
model of pain such as will be discussed in Chapter V or even in a mammalian model for 
pain (193), could lead to an appreciation for the role of PGHS-2 mediated 2-AG 
metabolism, in mediating pain. 
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CHAPTER V 
 
 
EVALUATION OF PGHS-2 MEDIATED OXYGENATION OF THE 
ENDOCANNABINOID 2-AG IN THE NEURONAL MILLEU 
 
Introduction 
The endocannabinoid system was discovered when an endogenously produced 
lipid was found to agonize the G-protein-coupled cannabinoid receptor (CB1) (149). This 
lipid was identified as an amide of AA with ethanolamine (arachidonoyl ethanolamine, 
AEA) (Figure 1). Soon thereafter, another endogenously produced lipid CB ligand was 
discovered. It was a glyceryl ester of AA, 2-arachidonoyl glycerol (2-AG) (Figure 1) 
(150).  
 
 
 
Figure 1.  Structures of the endocannabinoids 
 
Although a number of other lipids produced in vivo have been shown to agonise CB 
receptors, AEA and 2-AG remain the best understood and most physiologically relevant 
(144). The CB1 receptor is the most abundant GPCR in the mammalian brain, 
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hightlighting the importance of endocannabinoid signalling. The pertussis toxin (PTX) 
sensitive Gi/o CB1 receptor is expressed primarily in the hippocampus, basal ganglia, 
cerebellum, brain stem, spinal cord and dorsal root ganglia (180). Endocannabinoids have 
been shown to tonically modulate neuronal transmission in the rostral vental medulla 
(RVM), the periaqueductal grey and the spinal trigeminal nucleus, areas critically 
involved in the promotion of central analgesia (190-192). Supporting the importance of 
these areas in the modulation of pain, is the fact that treatment of these areas with a CB1 
receptor antagonist leads to the induction of hyperalgesia, in a opioid–independent 
manner (233,234). Noxious and painful stimuli from the periphery create neuronal 
hyperexcitablity in the dorsal horn of the spinal cord; this hyperexcitablity leads to 
increased glutaminergic signaling and excitotoxicity that induces the expression of 
Prostaglandin H Synthase-2 (PGHS-2) via production of inflammatory cytokines, such as 
IL-1β (67,235).  
PGHS-2 has been shown to oxygenate the endocannabinoid 2- arachidonoyl 
glycerol (2-AG) in vivo and ex vivo, leading to the formation of prostaglandin glyceryl 
esters (PG-Gs). Since 2-AG is also subject to hydrolysis to arachidonic acid (AA) by 
monoacylglycerol lipase (MAGL), the relevance of 2-AG metabolism by PGHS-2 has 
been called into question. Infinitesimal amounts of PG-Gs have been detected in both 
inflamed and non-inflamed rat footpad, probably owing to their rapid hydrolysis to 
traditional AA-derived prostaglandins (PGs) by an unidentified specific serine hydrolase 
(177,179). Furthermore, while the steady state kinetic parameters of the oxygenation of 
2-AG and AA by PGHS-2 in vitro are virtually identical (174), examination of the 
formation of PG-Gs ex vivo upon stimulation of murine resident peritoneal macrophages 
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with an inflammatory stimulus demonstrates that they are detected at levels 1000-fold 
lower than those of AA-derived prostaglandins (PGs) (176).  While the levels of 2-AG 
released upon stimulation by an inflammatory stimulus are only 10-fold lower than the 
levels of AA, there is incongruity between the levels of 2-AG and PG-Gs realized (176).  
That said, PGE2-G has been shown to effect Ca2+ mobilization in RAW264.7 
macrophages and H1819 non-small cell lung carcinoma cells at sub-picomolar 
concentrations, indicating that PG-Gs may be active at very low concentrations 
(178,215). PGE2-G also induces hyperalgesia (exaggerated pain sensation) and 
mechanical allodynia (nociception in response to non-nociceptive stimuli) in rats, acting 
through a unique, unidentified receptor (179).  Therefore, the oxygenation of 2-AG by 
PGHS-2 not only terminates analgesic endocannabinoid signaling, but also creates novel 
molecules that bear unique nociceptive activities.  
To date, there has been no demonstration of the formation of PG-Gs from the 
neuronal milieu. Pivotal to making a case for the role of PGHS-2 in the metabolism of 2-
AG in vivo, we have taken two approaches to determine the PG-G generating capacity in 
the neuronal environment. The first is directly assessing the production of PGs and PG-G 
in cerebrospinal fluid (CSF) in the rat carrageenan–footpad pain model. Peripheral pain 
has been shown to induce the expression of PGHS-2 in dorsal root ganglia and in the 
sensory dorsal horn via the production of inflammatory cytokines such as IL-1β 
(64,236,237). This phenomenon is what leads to central sensitization in response to 
peripheral pain, leading to an amplification of pain. CSF bathes the entire central nervous 
system, meaning products from oxidative metabolism of AA and 2-AG should be 
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detectable therein (64,236,237). Furthermore, extraction of CSF from rats has been used 
to detect neuropeptides and hormones by a previously published technique (238). 
  The second approach to determining neuronal capacity to generate PG-Gs is in 
primary cultures of murine dorsal root ganglia (DRG), which are collections of neurons 
that feed information from the periphery into the sensory horn of the spinal cord. 
Inflammatory stimuli have been shown to induce PGHS-2 in DRGs, which leads to a 
hyperexcitability that is transmitted into the sensory dorsal horn of the spinal cord (235). 
Hyperexcitability is associated with hyperalgesia and allodynia due to a large increase in 
the gain in the sensory system.  Using both of these approaches, we find that while we 
cannot detect PG-Gs in CSF, PGs were detected and associated with carrageenan-induced 
footpad inflammation, consistent with prior reports (64,236,237). Primary DRG cell 
cultures demonstrate robust PG and PG-G generation in response to various physiological 
inflammatory stimuli along with Ca2+ ionophores. This is the first demonstration that 
there are robust levels of PG-Gs formed in neuronal tissues in response to inflammatory 
stimuli.  Furthermore, while PGE2-G is produced by inflamed DRG cultures, it is rapidly 
degraded in DRGs. This adds to increasing evidence that PG-Gs are rapidly degraded in 
the ex vivo setting, adding difficulty to their detection and demonstration of relevance. 
Since DRG primary cultures primarily consist of microglia and neurons, we have 
determined that the source of PG-Gs is the microglia and not the neurons.  
Beyond these findings, we have established the DRG primary cell culture as a 
suitable platform for screening for agents that selectively inhibit the oxygenation of 2-AG 
by PGHS-2. As a proof of concept, here we demonstrate that an inactive enantiomer of a 
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commonly used NSAID R-flurbiprofen is a potent inhibitor of 2-AG and AEA 
oxygenation in DRG primary cultures.  
 
Experimental Procedures 
 
Induction of carrageenan-induced footpad inflammation in the rat - Carrageenan 
(100 µL, 1% (w/v), Fluka, dissolved in sterile physiological saline) was injecected 
subcutaneously into the plantar side of the right hind paw of adult male Sprague-Dawley 
rats while under light isoflurane anesthesia. Local inflammation was assessed by 
measurement of paw thickness using a plethysmometer. Sham-treated rats were injected 
with 100 µL of saline. Inflammation was allowed to develop for 2 hours.  
Assay for production of PGs and PG-Gs from rat CSF - Adult male Sprague-
Dawley rats were euthanized using isoflurane. CSF was extracted using 25-gauge insulin 
needles inserted into the cisterna magna. The position of the cisterna magna was 
determined by palpitation along the nuchal line on the rat’s occiput ending at C1. The 
syringe was inserted ~5mm into the space between cervical vertebrae C1 and C2, and 
CSF was aspirated. CSF (50 µL- 150 µL) was spiked with 20 µL of a solution containing 
deuterated standards as follows : 100 pmol of the following: PGD2-d4, PGE2-d4, PGF2α-
d4, 6-keto-PGF1α-d4, and 10 pmol of the following: PGD2-G-d5, PGE2-d5 PGF2α-d5, 6-
keto-PGF1α-G-d5, and 150 µL methanol:water (50:50 v:v). Samples were stored at -80° 
C until LC/MS analysis as previously published (217). 
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Isolation of embryonic dorsal root ganglia - Pregnant (E14-15) mice were 
euthanized by CO2 asyphyxiation. Embryos were surgically removed from the uterus of 
the euthanized mouse, and had their entire spinal column dissected and dorsal root 
ganglia (DRGs) collected. DRGs were washed in PBS and dissociated by incubation in 
0.001% collagenase/DNase and 0.15% trypsin at 37°C for one hour. Cells (80,000) were 
plated onto acid-treated, collagen-coated coverslips in 35 mm dishes and incubated in 3 
mL of UltraCulture Medium (10% Hyclone FBS, 1 mM L-glutamine, 1% Pen-Strep and 
50 ng/mL nerve growth factor). Cells were cultured at 37 °C and 5% CO2. 
Generation of pure neuronal DRG Cultures - Following the isolation of DRG 
described above, cultures were allowed to acclimatize for 48 hours at 37 °C and 5% CO2. 
Cells were then treated with 5 µM cytosine arabinoside (AraC) for 7 days, and confirmed 
to be pure neuronal cells by microscopic inspection. 
Induction of inflammation in DRG cultures and immunoblotting for PGHS-2 
expression – Following the 48 hour acclimation period, DRG cultures were treated with 
vehicle (sterile phosphate-buffered saline with 0.1% bovine serum albumin) or 20,000 
U/mL IFNγ (R&D systems) or 50 ng/mL IL-1β (R&D systems) for 24 hours. The 
medium was collected and frozen at -80°C until extraction. Cells were incubated in fresh 
medium with 2 µM ionomycin for 4 hours and the medium was collected and stored at -
80°C until extraction for LC/MS/MS analysis. Cells were scraped into lysis buffer and 
immunoblotted for PGHS-2 expression as previously described (239), with some 
modifications as follows: cells were lysed in 200 µl M-PER lysis buffer (Thermo) 
containing a cocktail of  mammalian protease inhibitors (Sigma). Cell lysates were mixed 
by vortexing and placed on ice for 30 min. Cellular debris was then removed by 
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centrifugation for 10 min at 16,000 g.  Samples were stored at -80 °C until analyses could 
be completed. Equal quantities of protein (~ 20 µg) were resolved by gradient (2 - 12%) 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a 
polyvinylidene difluoride membrane (Immobilon-P, Millipore). Membranes were 
blocked (20 mM Tris, pH 7.6, 140 mM NaCl, 0.05% Tween 20, 5% nonfat dry milk) 
prior to incubation with antibodies. Both primary antibodies (α-actin and α-PGHS-2, 
Cayman Chemical, USA) were used at 1:1000 dilution and the secondary antibody 
(Cayman Chemical, USA) at 1:5000 dilution. 
Assay for Production of PGs and PG-Gs from Cell Culture- Medium from cell 
culture was subjected to liquid-liquid extraction as developed by Philip Kingsley with 
some modifications. Briefly, internal standards (100 pmol of the following: PGD2-d4, 
PGE2-d4, PGF2α-d4, 6-keto-PGF1α-d4, and 10 pmol of the following: PGD2-G-d5, PGE2-
d5 PGF2α-d5, 6-keto-PGF1α-G-d5 2 mL media was acidified by the addition of 1% 
glacial acetic acid, followed by 2 mL of ETOH and 2 mL  Hexanes:Ethyl Acetate 
(20:80). Samples were vortexed and centrifuged at 3000 RPM for 20 minutes. The 
organic layer was retrieved and dried down under a stream of nitrogen. Samples were 
resuspended in 300µL Methanol:Water (50:50) and analyzed as previously described 
(217). 
Results 
Assay of PG and PG-G Formation in CSF in Response to Peripheral 
Inflammation- Comparative LC/MS analysis of CSF from saline-treated rats and rats with 
carrageenan-induced footpad inflammation revealed that PG-Gs could not be detected 
under either of these conditions (data not shown). Even though PG-Gs have been shown 
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to be stable in CSF (177), it is possible that they may be rapidly hydrolyzed within the 
ventricular system, by serine hydrolase(s) expressed in cells within the ventricular 
system. Further analysis revealed that the CSF from saline-treated control rats did not 
contain PGs, but CSF from rats with carrageenan-induced inflammation of the foot 
contained significant quantities of pro-inflammatory PGE2 (Figure 2 and 3).  This is in 
line with recent work demonstrating that PGE2 is detectable in CSF of rats with 
carrageenan-induced footpad inflammation (240).  
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Figure 2.  Assay of PGs in rat CSF WITHOUT inflammation  –Rat 1 and Rat 2 were 
sham treated (saline) as controls to assay baseline PG formation.  PGs and PG-Gs (not 
shown) were undetectable in the CSF of these rats. 
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Figure 3.  Assay of PGs in rat CSF WITH carrageenan-induced rat footpad 
inflammation  –CSF from Rat 3 and Rat 4 revealed that PGE2 is generated in the spinal 
cord in response to peripheral pain and inflammation. This is in line with recent reports 
demonstrating that peripheral inflammation can lead to PGE2 production in the spinal 
cord. PG-Gs were undetectable in these rats (not shown). 
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Assay of PG-G formation in DRG Cultures in Response to Inflammation- LC/MS 
analysis of medium from cells treated as described in “Experimental Procedures” 
indicated that under control conditions, modest amounts of PGs are formed (Figure 4). 
PG generation was increased in DRG cultures pre-treated with the physiologic 
inflammatory agonists, IFNγ and Il-1β, consistent with literature findings that these two 
cytokines induce PG synthesis in DRG cultures by upregulating PGHS-2 expression 
(65,66). Immunoblotting for PGHS-2 demonstrates that both IFNγ and Il-1β induce 
PGHS-2 (Figure 5). Interestingly, the stable PGI2-G metabolite, 6-keto-PGF1α-G was 
only found in cultures treated with either IFNγ or Il-1β, followed by ionomycin (Figure 
4). Ionomycin on its own did not lead to the generation of any PG-Gs. This is the first 
demonstration of the formation of a PG-G in primary neuronal cultures. A time course of 
the production of PG-Gs was conducted and the data were plotted (Figure 6).  Here we 
expand the initial observation and demonstrate that PGE2/D2-G and PGF2α-G are 
generated in addition to the previously detected PGI2-G metabolite (6-keto-PGF1α-G), 
and at levels that are 10-fold higher than 6-keto-PGF1α-G (Figure 6). A time course of 
PG-G production reveal that PGE2-G levels peak at 2 hours, and drop precipitously by 4 
hours, indicating that PGE2-G is unstable under these conditions (Figure 7). This is 
probably due its hydrolysis to PGE2 by a yet to be identified esterase (177). Surprisingly, 
PGF2α-G levels remain high through out the time course, and seemingly not as unstable 
as PGE2-G (Figure 7). This is the first time PG-Gs have been demonstrated in primary 
neuronal culture. 
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Assay of PG and PG-G formation in pure neuronal DRG cultures in response to 
inflammation - Pure neuronal DRG cultures were prepared as described in “Experimental 
Procedures”.  The pure population of neurons did not generate any detectable amounts of 
PG-Gs (data not shown), and PG production was diminished relative to mixed cultures 
containing microglia. In fact the only PG generated under these conditions is PGE2 
(Figure 8). This indicates that the microglia are the chief source of PG-Gs in these cell 
culture systems. Also, to determine if the hydrolysis of 2-AG prevented the oxygenation 
of 2-AG released from the neurons, we co-incubated a potent irreversible MAGL 
inhibitor, JZL-184 (170) at 1µM for 30 minutes before the beginning of the experiment. 
However, as stated earlier, pure neuronal cultures of DRGs did not produce any PG-Gs. 
Infact, inhibition of MAGL seemed to affect PGE2 generation (Figure 8). 
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Figure 4.  Assay of PG-G formation in DRG Cultures in Response to Inflammation 
–Primary DRG cultures were pre-treated for 24hours with IFNγ and IL-1β. and PG and 
PG-G formation was evoked by treating these cultures with  ionomycin for 4 hours.  
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Figure 5. Determination of PGHS-2 levels in DRG cultures treated with IFNγ  and 
IL-1β .  (A) Immunoblot for PGHS-2 was conducted as described in “Experimental 
Procedures”. PGHS-2 levels are almost undetectable in unstimulated cells, whereas either 
IFNγ or IL-1β  treatment leads to a large upregulation of PGHS-2. 
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Figure 6.  Assay of PG and PG-G formation in DRG cultures in response to 
inflammation –Primary DRG cultures were pre-treated for 24hours with IFNγ and IL-
1β. and PG (A) and PG-G  (B)formation was evoked by treating these cultures with  
ionomycin for 2 hours as opposed to the 4 hour time treatment described initially.  
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Figure 7.  Time course of PG-G formation in DRG cultures in response to 
inflammatory agonist, IFNγ  – Primary DRG cultures were pre-treated for 24 hours with 
IFNγ. PG-G formation was evoked by treating these cultures with ionomycin for 2, 3, and 
4 hours. Results were from single determination. 
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IFN, pure neuronal cultures were generated as described in “Experimental Procedures”. 
Pure neuronal cultures did not produce any detectable PG-Gs (not shown).  
 
Assay of inhibition of PG and PG-G formation in DRG Cultures in Response to 
Inflammation - Following the determination that DRG cultures produced robust levels of 
PG-Gs in response to a physiologic inflammatory agonist, we determined the capacity of 
the poorly active enantiomer of flurbiprofen, R-flurbiprofen, to inhibit the oxygenation of 
2-AG in inflamed DRG cultures.  R-Flurbiprofen has been shown to be a potent selective 
inhibitor of 2-AG oxygenation in vitro (Kelsey Duggan, personal communication). Here 
we show that R-flurbiprofen is a potent selective inhibitor of 2-AG and AEA oxygenation 
in inflamed DRG cultures (Figure 9). We have also expanded our analysis to AEA-
derived products, upon the demonstration that these cultures also release appreciable 
amounts of AEA upon stimulation with Ca2+ ionophore (Daniel Hermanson, personal 
communication). 
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Figure 9.  Assay for R-flurbiprofen-mediated inhibition of PG, PG-EA, and PG-G 
formation in DRG cultures in response to an inflammatory agonist - Primary DRG 
cultures were pre-treated for 24 hours with IFNγ and then pre-incubated with increasing 
concentrations of R-flurbiprofen for 2 hours. Product formation was evoked by treating 
these cultures with ionomycin for 2 hours. 
 
Discussion 
The present study establishes that the inflammatory prostaglandin PGE2 is present 
in the CSF of rats with carrageenan-induced pain and inflammation. While the chief 
source of PGE2 is AA oxygenation by PGHS, the lack of detection of its 2-AG-derived 
congener might imply that PGE2-G is rapidly hydrolyzed to PGE2. While PGE2-G is 
chemically stable in CSF, it is not implausible that serine hydrolases in the ventricular 
system that the CSF bathes could metabolize PGE2-G to PGE2. Our study also highlights 
a recently reported phenomenon where peripheral pain induces central sensitization 
leading to PGHS-2 induction and PG production (240). This study and the present work 
indicate that PGE2 could be a useful pain biomarker, as it is unequivocally associated 
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with pain in relatively linear manner (64). Partly due to the prevalence of pain medicine 
abuse and our poor understanding of the pathology of pain, pain is overwhelmingly 
undertreated. Having a biomarker that can be rapidly and reliably assayed for efficacy of 
treatment would be indispensable. 
While the present study failed to detect PG-Gs in CSF, we demonstrate for the 
first time that 2-AG is oxygenated by PGHS in primary neuronal cultures, in response to 
two physiologically relevant inflammatory agonists.  The importance of the inflammatory 
response in the generation of PG-Gs is seen when the neuronal population of 
macrophages (microglia) are eliminated; PG-G generation is completely abrogated 
(Figure 6). Microglia respond to IFNγ and IL-1β by upregulating PGHS-2 (65,66).  This 
possibly implies that the neurons could be the source of 2-AG that is subsequently 
oxygenated by the PGHS-2 expressed in microglia. Further work to elaborate this 
connection is needed. As with previous work, we also demonstrate that PGE2-G is rapidly 
degraded in primary DRG cultures, even though PGF2α-G seems particularly stable. 
Determination of the metabolism of PG-G under these conditions is warranted. The levels 
of PG-Gs produced in these cultures are at levels 50-fold higher than those shown for the 
action of PG-Gs on G-protein coupled receptors (GPCRs). PGE2-G and PGF2α-G have 
been shown to mobilize Ca2+ at sub-picomolar concentrations and in a concentration 
dependent manner, in RAW264.7 macrophages and H1819 non-small cell carcinoma 
cells (178,215). This indicates that the levels of PG-Gs produced in response to 
inflammatory agonists are sufficient to activate these pathways, and warrant 
investigation.  Dissection of the effects of the production of PG-Gs in DRGs could lead to 
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the identification of the unique and yet to be identified receptor that mediates the actions 
of PG-Gs already demonstrated. 
Finally, this work demonstrates that primary DRG cultures are a robust ex vivo 
system to study the oxidative metabolism of 2-AG by PGHS-2. Here, we translate in vitro 
work demonstrating that a potent substrate selective inhibitor, R-flurbiprofen, is a potent 
selective inhibitor of 2-AG and AEA oxygenation.  These studies could lead to the 
determination of the contribution of PGHS-2-mediated oxygenation of 2-AG and AEA in 
pain. 
	   148	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CHAPTER VI 
 
 
SUMMARY 
 
 
 
PGHSs catalyze the oxygenation of fatty acyl substrates (FAH) such as 
arachidonic acid (AA). This is the committed step in the generation of prostaglandin H2  
(PGH2). PGH2 is the substrate for five downstream isomerases that lead to the generation 
of prostaglandins. Prostaglandins mediate a variety of physiological effects, such as pain, 
inflammation, fever, vascular homeostasis, and parturition, by their actions at several 
prostaglandin-specific G-protein coupled receptors (GPCRs).  The endogenous ligands 
for the cannabinoid receptors, arachidonoyl ethanolamine (AEA) and 2-arachidonoyl 
glycerol (2-AG) are substrates for the second isoform of PGHS, PGHS-2. Their 
oxygenation leads to the generation of AEA and 2-AG derived prostaglandins (PG-EAs 
and PG-Gs). PG-Gs have been shown to have unique actions at yet to be identified 
GPCRs including, mobilizing Ca2+ at the picomolar level in cell culture, and causing a 
concentration dependent hyperalgesia (exaggerated pain) and allodynia (pain in response 
to non-pain evoking stimuli).  Despite these findings, PG-Gs have been detected at low 
levels in vivo, and ex vivo are only detectable at levels 1000-fold lower than their free 
acid counterparts, PGs. The in vitro kcat/Km values for 2-AG and AA with PGHS-2 are 
comparable, and this disparity in product formation ex vivo has led us to hypothesize that 
there are factors not apparent in the kcat/Km of 2-AG with PGHS-2, that affect its 
oxygenation relative to AA.  The work presented herein, represents efforts to determine 
the in vitro biochemical determinants of 2-AG oxygenation by PGHS-2, and as an 
extension of this work, I demonstrate that these determinants are similar ex vivo, and 
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furthermore, that in the neuronal milleu, 2-AG is robustly oxygenated by PGHS-2, 
leading to the formation of PG-Gs. In sum, this work provides further credence to the 
physiological relevance of PGHS-2-mediated oxygenation of 2-AG. 
The activation of oxygenase activity of PGHS requires turnover at the peroxidase 
(POX) active site of PGHS, leading to the activation of the catalytic residue, Tyr385, in 
the oxygenase site. This converts it to a tyrosyl radical, which initiates oxgenation of 
FAH. Since the turnover of 2-AG in murine macrophages was so low, I hypothesized that 
2-AG derived peroxides such as 15-HpETE-G and PGG2-G are poorer substrates at the 
POX active site, leading to poorer activation of 2-AG oxygenation relative to AA. To test 
this hypothesis, I generated a surrogate for the chemically unstable 2-AG-derived PGG2-
G, 15-HpETE-G, and its free acid AA-derived counterpart 15-HpETE. 15-HpETE and 
15-HpETE-G did not differ significantly in their disposition as POX substrates and are 
equivalent substrates and activators of PGHS’s oxygenase activity.  Furthermore, 
qualitative examination of the levels of reduction of in situ generated PGG2 and PGG2-G 
demonstrates that both AA derived PGG2 and 2-AG derived PGG2-G are reduced to a 
similar extent by the POX activity of PGHS. This eliminated the possibility that the 
glyceryl ester on PGG2-G affects the rate of its reduction by the POX active site of 
PGHS.  While the Kms for 15-HpETE and 15-HpETE-G for the POX active site of PGHS 
were comparable, the concentration of peroxide required to activate the COX active site 
of PGHS-2 for oxygenation of 2-AG had not been determined. This value, Kp, is a 
concentration that can be determined from co-incubations of PGHS and the substrate in 
question, in the face of increasing levels of glutathione peroxidase (GPx). Testing of 2-
AG and AA led to a dimunition of oxygenation of 2-AG that was significantly greater 
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than that of AA, at any of the concentrations of GPx tested. Furthermore, calculation of 
the Kp from linear regression analysis of the traces of the decay of oxygenation with AA 
and 2-AG demonstrated that the Kp of 2-AG was  ~ 3-fold higher than AA’s. This 
indicated that the activation of oxygenation of 2-AG by PGHS-2 requires at least 3-fold 
higher concentrations of peroxide to activate the oxygenation of 2-AG by PGHS-2.  
Further confirmation of the exquisite sensitivity of 2-AG oxygenation to peroxide-
mediated activation was demonstrated by the severely impaired turnover of 2-AG by a 
POX active site mutant of PGHS-2, H388Y PGHS-2, which retains less than 1/300 of wt 
PGHS-2’s POX activity. H388Y PGHS-2 can still oxygenate AA to the same extent as wt 
PGHS-2, however its reaction trajectory is characterized by a lag phase, during which 
PGG2 levels reach levels sufficient to achieve activation of COX activitity in latent 
H388Y PGHS-2.  Examination of the levels of PGG2 and PGG2-G over the course of 
oxygenation by H388Y PGHS-2 reveals that PGG2-G levels are greatly diminished over 
the entire time course, and never approach the levels of PGG2 determined under these 
conditions. Wt PGHS-2 levels of 2-AG oxygenation were restored by exogenous 15-
HpETE or 15-HpETE-G and in a concentration dependent manner.  2-AG oxygenation 
by PGHS-2 bears striking resemblance to the oxygenation of an ω-3 fatty acid, 
eicosapentaenoic acid (EPA). EPA is also substrate for PGHS-2 and its oxygenation by 
H388Y PGHS-2 is also severely impaired, and can be restored to wt PGHS-2 levels via 
co-incubation with increasing concentrations of peroxide. The crystal structure of EPA 
with PGHS reveals that the 13-pro-(S)- hydrogen on the FAH backbone of EPA is shifted 
away from COX catalytic residue, Tyr385.  Determination of the Kp of EPA with PGHS-
2 reveals that its Kp is 20-fold greater than AA’s with PGHS-2. The binding mode of 2-
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AG in the COX active site of PGHS has been proposed by our lab, based on extensive 
mutagenesis studies, however, these findings have not been confirmed by 
crystallography. It is therefore possible that the 13-pro-(S)- hydrogen on the FAH 
backbone of 2-AG, like EPA, is shifted away from Tyr385, leading to an increased Kp. 
These results indicated that the initiation of PGHS-2 mediated oxygenation of 2-
AG is sensitive to peroxide tone. I hypothesized that this sensitivity partly explains the 
poor recovery of PG-Gs from the ex vivo setting. To test my hypothesis, I used shRNA to 
stably deplete the levels of two of the major components of the endogenous peroxide 
detoxification mechanisms, glutathione peroxidase 1 (GPx1) and glutathione peroxidase 
4 (GPx4) in murine fibroblasts. Murine fibroblasts can oxygenate both AA and 2-AG 
leading to the recovery of PGs and PG-Gs. Depletion of GPx4 in these fibroblasts led to a 
3-fold increase in lipid peroxidation and a significant increase in the levels of 
isoprostanes in these cells relative to control.  A concomitant increase in PGE2-G (2-fold) 
and PGF2α-G (4-fold) production following inflammatory stimulus was also observed in 
cells with depleted GPx4, relative to control. GPx1 depleted cells did not differ from 
control. These results indicated peroxide tone is important for PGHS-2 mediated 2-AG 
oxygenation, and indicates that under conditions of increased oxidant stress, 2-AG 
oxygenation in augmented.  
These results indicated that the POX active site of PGHS could be a veritable 
pharmacological target for the modulation of 2-AG oxygenation.  To test this hypothesis, 
I designed a ligand based one the binding parameters for PGG2 in the POX active site of 
PGHS. Testing of our lead compound 2-methyl-4,5-dihexylimidazole demonstrated that 
it was a modest POX inhibitor, and the first of its kind. It was exciting to demonstrate 
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that even with modest inhibition of the POX active site, I could selectively and potently 
inhibit the PGHS-2-mediated oxygenation of 2-AG over that of AA. Furthermore, testing 
in a murine macrophage cell line treated with inflammatory agonist revealed that 2-
methyl-4,5-dihexylimidazole was an extremely potent and selective inhibitor of 2-AG 
oxygenation. These efforts have generated an extremely useful tool for the dissection of 
the PGHS-2/2-AG axis, and could lead to a delineation of the role of PGHS-2 in 
endocannbinoid metabolism. 
Finally, and very importantly, I examined the formation of PG-Gs and PG-EAs in 
the neuronal milieu in the context of inflammation. For the first time, we demonstrate that 
primary murine neuronal cultures oxygenate endogenously produced AEA and 2-AG to 
form PG-EAs and PG-Gs. This finding finally thrusts PGHS-2 into the fore in terms of its 
role in endocannabinoid metabolism in the neuronal context. Even more powerful, is the 
demonstration that the primary neuronal culture is an extremely useful platform for the 
testing of agents that can selectively inhibit the oxygenation of 2-AG over that of AA. 
This could potentially lead to compounds that could be useful in dissection of the PGHS-
2/2-AG axis, especially in determining the role of PGHS-2 mediated oxygention of 2-AG 
and AEA in mediating pain. 
This work opens up new avenues of inquiry by providing validation that the 
PGHS-2 mediated oxygenation of endocannabinoids AEA and 2-AG is relevant to the 
cell, and has created tools that can be used to further examine the relevance of this 
metabolism in both physiology and pathology. 
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DETERMINANTS OF CYCLOOXYGENASE-2-MEDIATED OXIDATIVE METABOLISM OF THE 
ENDOCANNABINOID, 2-ARACHIDONOYL GLYCEROL, IN VITRO AND EX VIVO 
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PGHSs catalyze the oxygenation of fatty acyl substrates (FAH) such as 
arachidonic acid (AA). This is the committed step in the generation of prostaglandin H2  
(PGH2). PGH2 is the substrate for five downstream isomerases that lead to the generation 
of prostaglandins. Prostaglandins mediate a variety of physiological effects, such as pain, 
inflammation, fever, vascular homeostasis, and parturition, by their actions at several 
prostaglandin-specific G-protein coupled receptors (GPCRs).  The endogenous ligands 
for the cannabinoid receptors, arachidonoyl ethanolamine (AEA) and 2-arachidonoyl 
glycerol (2-AG) are substrates for the second isoform of PGHS, PGHS-2. Their 
oxygenation leads to the generation of AEA and 2-AG derived prostaglandins (PG-EAs 
and PG-Gs). PG-Gs have been shown to have unique actions at yet to be identified 
GPCRs including, mobilizing Ca2+ at the picomolar level in cell culture, and causing a 
concentration dependent hyperalgesia (exaggerated pain) and allodynia (pain in response 
to non-pain evoking stimuli).  To determine the biochemical determinants of the 
oxygenation of 2-AG by PGHS-2, I compared the abilities of AA derived hydroperoxides 
to 2-AG derived peroxides as substrates and activators of the oxygenase function of 
PGHS. I demonstrated that PGG2 and PGG2-G were both equivalent substrates for 
PGHS-2. Interestingly, the oxygenation of 2-AG demonstrated and increased need for the 
concentrations of peroxide required to activate its oxygenation.  In the presence of 
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increased peroxide scavenging by glutathione peroxide (GPx), the oxygenation of 2-AG 
was almost abrogated compared to relatively unaffected AA oxygenation. Specifically, I 
demonstrated that the depletion of the membrane associated GPx (GPx4), leads to 
increased oxidant stress and peroxide tone, and significantly increased oxygenation of 2-
AG in murine derived cells. 
These results led us to conclude that the oxygenation of 2-AG is exquisitely 
sensitive to the concentration of oxygenase activating peroxide. Chemical ligands 
specifically designed to target the peroxidase active site of PGHS have to date not been 
reported. I designed a chemical mimic of PGHS-2 substrate PGG2 and developed a 
chemical ligand that inhibited the turnover of peroxide at the peroxidase active site of 
PGHS. This lead compound forms a new class of molecule that can specifically and 
potently inhibit the oxygenation of 2-AG by PGHS-2, while having no impact on AA 
oxygenation. It could form a useful tool for the dissection of the physiological role of 
PGHS-2 mediated 2-AG oxygenation. 
  
 
